Transcription Factor-Based Fate Specification and Forward Programming for Neural Regeneration

Lea J. Flitsch, Karen E. Laupman and Oliver Brüstle*

Institute of Reconstructive Neurobiology, Life & Brain Center, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany

Traditionally, in vitro generation of donor cells for brain repair has been dominated by the application of extrinsic growth factors and morphogens. Recent advances in cell engineering strategies such as reprogramming of somatic cells into induced pluripotent stem cells and direct cell fate conversion have impressively demonstrated the feasibility to manipulate cell identities by the overexpression of cell fate-determining transcription factors. These strategies are now increasingly implemented for transcription factor-guided differentiation of neural precursors and forward programming of pluripotent stem cells toward specific neural subtypes. This review covers major achievements, pros and cons, as well as future prospects of transcription factor-based cell fate specification and the applicability of these approaches for the generation of donor cells for brain repair.

Keywords: forward programming, transcription factor-driven differentiation, direct cell fate conversion, biomedical application, translation, transplantation, brain repair

INTRODUCTION

Identifying treatment options for neurological and especially neurodegenerative diseases is one of the most pressing tasks of modern biomedicine. In this context, neural cell replacement has emerged as a particularly promising strategy, which has gained further impetus with the availability of massively scalable human PSCs. A key prerequisite for the use of human PSCs in neural repair is the efficient derivation of disease-specific cell populations. Over the last 20 years, numerous in vitro differentiation protocols were established. Classically, they involve extrinsic factors such as morphogens to guide the differentiation process toward a specific cell fate, thereby mimicking regionalization processes during nervous system development. This approach has led to significant advances, for instance, for the generation of midbrain dopamine neurons for the treatment of PD (Kriks et al., 2011; Kirkeby et al., 2012). However, the generation of many neural subtypes is frequently complicated by long differentiation times and complex multi-step growth factor-regimens, which often yield cultures exhibiting a high degree of heterogeneity (see also review by Tao and Zhang, 2016). Thus, many growth factor-based protocols have to be regarded as insufficiently precise when it comes to fine-tuning the specification of distinct neural subtypes, especially considering future biomedical applications.

Since morphogen-based cell specification finally converges on the activation of specific transcriptional programs, TF overexpression by itself represents an alternative method to guide cell
fate acquisition. This idea was further fueled by the ground-breaking discovery by Takahashi and Yamanaka that an ESC-like pluripotent fate can be induced in mouse (Takahashi and Yamanaka, 2006) and human (Takahashi et al., 2007) somatic cells by overexpressing a combination of four different TFs, namely Oct3/4, Sox2, Klf4 and c-Myc. The introduction of the iPSC reprogramming technology had two major implications for the scientific field: First, the feasibility to reprogram terminally differentiated somatic cells into iPSCs hinted at the potential power of exploiting TF overexpression as a tool to manipulate cell fates more globally. Second, it created the general opportunity to derive neural cells from basically any adult human and thus revealed new avenues for disease modeling and personalized biomedicine.

In line with the first idea is the concept of direct cell fate conversion, i.e., the use of TFs to directly convert one somatic cell type into another without transiting a stable, pluripotent state. In fact, direct cell fate conversion has been achieved far before the iPSC technique was even introduced: Davis et al. (1987) successfully converted mouse fibroblasts into myoblasts by overexpressing the TF Myod3. As for neurons, it had already been shown by Magdalena Götz and colleagues in the early 2000s that mouse astrocytes can be directly converted into neurons by overexpressing single neural TFs such as Pax6 (Heins et al., 2002), Olig2 (Buatto et al., 2005), Ngn2 and Ascl1 (Berming et al., 2007). In 2010, the Wernig lab achieved to derive iNs from mouse fibroblasts via transdifferentiation across germ layers (Vierbuchen et al., 2010). Although in this case Ascl1 overexpression seemed sufficient to drive neuronal conversion, too, the derivation of mature iNs was most efficient when multiple TFs were used simultaneously, such as the combined expression of Ascl1, Brn2 and Myt1l (Vierbuchen et al., 2010). This TF cocktail alone (Pfisterer et al., 2011a,b) or in combination with the bHLH TF NEUROD1 (Pang et al., 2011) was shown to suffice for inducing iNs from human fibroblasts. In combination with SOX2, ASCL1 can also convert human non-neural, brain-resident pericytes into functional iNs (Karow et al., 2012, 2018).

How broadly TF overexpression can impact the differentiation of PSCs is illustrated by studies of Minoru Ko and colleagues, who established more than 180 mouse ESC lines, each expressing a distinct TF from the ROSA locus after doxycycline induction, which resulted in the specification of a large variety of different somatic cell lineages (in the following also referred to as ‘forward programming’; Nishiyama et al., 2009; Correa-Cerro et al., 2011; Yamamizu et al., 2016).

The aim of this review is to give a comprehensive overview on TF-based approaches for the generation of neural cells (Figure 1). We will speculate on general mechanisms underlying TF-mediated neuronal differentiation and forward programming, specifically comment on current efforts to derive clinically relevant neuronal subtypes and glial cells, and summarize recent endeavors to apply these cells in vivo for brain repair. Finally, we will discuss forward programming as an alternative to direct cell fate conversion, and comment on the achievements as well as remaining hurdles for biomedical translation.

### DERIVATION OF NEURAL CELL TYPES VIA FORWARD PROGRAMMING

Specifying cell fates by TF overexpression is comparably easy to accomplish within one line, especially when starting from cell types which are direct progenitors of the target cell type. Almost 20 years ago, Sun et al. (2001) reported about the successful derivation of neurons by retrovirally overexpressing the neuronal bHLH TF Ngn1 in primary rat cortical NPCs (Table 1). Since then, other TFs belonging to the bHLH family have been shown to be capable of forcing neuronal differentiation from
FIGURE 1 | Transcription factor-mediated specification of pluripotent stem cells and neural precursor cells. PSCs, such as ESCs derived from the blastocyst or iPSCs reprogrammed from somatic cells, as well as primary or PSC-derived NPCs can be differentiated into neurons, astrocytes and oligodendrocytes via overexpression of cell type-specific TFs. By using subtype- and/or region-specific TFs, forward programming approaches can be further refined to yield highly specified neuronal subtypes as for instance midbrain dopaminergic neurons. The TFs listed for the derivation of diverse neural cell types were either used alone or in combination. Further details on TF combinations are provided in the main text and in Tables 1, 2.

different NPC populations. These TFs include various Ngn s such as Ngn1 (Serre et al., 2012; Song et al., 2017), Ngn2 (Geoffroy et al., 2009; Serre et al., 2012; Bolós et al., 2014; Ho et al., 2016; Li X. et al., 2016) and Ngn3 (Serre et al., 2012), Ascl1 (Geoffroy et al., 2009; Kim et al., 2009; Serre et al., 2012; Li X. et al., 2016; Barretto et al., 2020) as well as Neurod TFs (Hsieh et al., 2004).

bHLH Transcription Factors as Key Instructors of Neuronal Differentiation

Interestingly, also rapid neuronal differentiation of PSCs (this term will be used to describe ESCs and iPSCs together in the following), which are not yet committed to the neuronal lineage, was shown to be feasible with bHLH TFs. A milestone in the field of neuronal forward programming was reached in 2011, when the groups of Marius Wernig and Thomas Südhof reported that combined overexpression of the TFs Ascl1, Brn2, and Myt1l not only suffices to transdifferentiate mouse fibroblasts into neurons (Vierbuchen et al., 2010) but also efficiently drives neuronal specification from human PSCs (Pang et al., 2011). The authors revealed that ASCL1 is most crucial for neural fate acquisition, whereas the TFs BRN2 and MYT1L rather promote downstream neuronal maturation. Using the full TF cocktail, electrophysiologically active neurons can be derived from all PSCs after only 6 days of in vitro differentiation (Pang et al., 2011). Several other labs subsequently demonstrated that Ascl1 alone can efficiently forward program mouse ESCs (Yamamizu et al., 2013; Teratani-Ota et al., 2016) and human PSCs (Chanda et al., 2014; Robinson et al., 2016) toward a neuronal fate, albeit with slower differentiation dynamics than the full ASCL1, BRN2, and MYT1L TF combination: In mouse ESCs, overexpression of Ascl1 leads to a sharp increase of neural markers within the first 7 days of induction (Yamamizu et al., 2013; Teratani-Ota et al., 2016), and 11 days after overexpressing Ascl1, about half of the neurons were shown to generate action potentials upon current injection (Yamamizu et al., 2013). In human PSCs, ASCL1-overexpressing cells do not start to express neuronal markers such as TUBB3 and MAP2 before day 9 of differentiation. Still, ASCL1 overexpression alone is sufficient to generate morphologically and functionally mature neurons when ESC-derived immature neuronal cells are cultured in advanced neuronal differentiation medium and are grown on primary glial cells. These neurons not only exhibit mature electrophysiological properties such as spontaneous action potential firing after 4 weeks of differentiation but also respond to exogenous AMPA and GABA application and demonstrate signs of short-term synaptic plasticity, indicating the formation of functional synapses (Chanda et al., 2014).

Overexpression of other bHLH TFs, too, induces rapid neuronal differentiation of PSCs: In one of the first in vitro studies employing overexpression of Ngn1 in mouse ESCs, transduced cells underwent morphological rearrangements forming neurite-like structures already within the first 72 h and became electrophysiologically excitable as early as 4 days after transgene induction (Tong et al., 2010). After 5 days of Ngn2 overexpression, mouse ESC-derived cells express the mature neuronal marker Map2, display neuronal electrophysiological properties at day 10, and form synapses in co-culture with primary mouse hippocampal neurons 20 days post induction.
### TABLE 1 | Transcription factors used for promoting neuronal differentiation of neural precursor cells and pluripotent stem cells in vitro.

| Desired cell type | Starting cell type | Species | Transcription factor used for forward programming | References |
|-------------------|--------------------|---------|---------------------------------------------------|------------|
| Neurons (generic) | NPCs               | Mouse   | Pax6                                              | Hack et al. (2004) |
| NPCs              | Mouse              | Sox1    |                                                   | Ken et al. (2004) |
| NPCs              | Mouse              | Dominant-negative form of REST | Greenway et al. (2007) |
| NPCs              | Mouse              | Ascl1 or Ngn2 | GEOFFROY ET AL. (2009) |
| NPCs              | Mouse              | Ngn2    |                                                   | Bolos et al. (2014) |
| NPCs              | Mouse              | Sox4    |                                                   | Braccioli et al. (2018) |
| NPCs              | Mouse              | Zeb2    |                                                   | Yang et al. (2018) |
| NPCs              | Rat                | Ngn1    |                                                   | Sun et al. (2001) |
| NPCs              | Rat                | Neurod  |                                                   | Hsieh et al. (2004) |
| NPCs              | Rat                | Brn4    |                                                   | Shi et al. (2010) |
| NPCs              | Rat                | Dominant-negative form of REST | DeWald et al. (2011) |
| NPCs (under glia-promoting conditions) | ESC-derived NPCs | Mouse and human | Dlk1 | Surmacz et al. (2012) |
| NPCs              | Human              | ASCL1 |                                                   | Kim et al. (2009) |
| NPCs              | Human              | ASCL1 or Ngn1 or Ngn2 or Ngn3 | Serre et al. (2012) |
| NPCs              | Human              | ASCL1 or Ngn2 or ASCL1 + Ngn2 | (1) Li X. et al. (2016) |
| NPCs (primary and ESC-derived) | Human | shREST or shHAUSP | Huang et al. (2011) |
| iPSC-derived NPCs | Human              | NGN2 |                                                   | Ho et al. (2016) |
| iPSC-derived NPCs | Human              | ASCL1 + DLX2 | Barretto et al. (2003) |
| ESCs              | Mouse              | Neurod1 or Neurod2 or Neurod3 | O’Shea (2001) |
| ESCs              | Mouse              | Ngn1    |                                                   | Tong et al. (2010) |
| ESCs              | Mouse              | Ngn2    |                                                   | Thoma et al. (2012) |
| ESCs              | Mouse              | Ascl1 or Smad7 or Nrf2 | Yamamizu et al. (2013) |
| ESCs              | Mouse              | Multiple (TF screen) | Teratani-Ota et al. (2016) |
| ESCs              | Mouse              | Neurod1 |                                                   | Patsaskar et al. (2016) |
| ESCs              | Mouse              | Multiple (TF screen) | Liu et al. (2018) |
| ESCs              | Mouse              | sh-Inc-RNA-1604 + Zeb1 and/or Zeb2 | Weng et al. (2018) |
| ESCs              | Mouse              | Ngn2 or Ascl1 | Aydin et al. (2019) |
| PSCs              | Human              | ASCL1 + BRN2 + MYT1L | Pang et al. (2011) |
| PSCs              | Human              | NGN2 or NEUROD1 | Zhang et al. (2013) |
| PSCs              | Human              | ASCL1 |                                                   | Chanda et al. (2014) |
| iPSCs             | Human              | FOXG1 + SOX2 + ASCL1 + DLX5 + LHX6 | Coiasante et al. (2015) |
| iPSCs             | Human              | ASCL1 + DLX2 + LHX6 + miR9/9*-124 | (6) Sun et al. (2016) |
| iPSCs             | Human              | ASCL1 |                                                   | Robinson et al. (2016) |
| iPSCs             | Human              | Ngn2    |                                                   | Rubio et al. (2016) |
| iPSCs             | Human              | ASCL1 + DLX2 | (4) Yang et al. (2017) |
| iPSCs             | Human              | Ngn2    |                                                   | Fregi et al. (2017) |
| iPSCs             | Human              | NGN1 or Ngn2 or NGN3 or NEUROD1 or NEUROD2 | Goparaju et al. (2017) |
| iPSCs             | Human              | NGN1 or Ngn2 or NGN3 or NEUROD1 or NEUROD2 | Matsushiba et al. (2017) |
| iPSCs             | Human              | Ngn2    |                                                   | Pawlowski et al. (2017) |
| iPSCs             | Human              | Ngn2    |                                                   | Wang et al. (2017) |
| iPSCs             | Human              | Ngn2    |                                                   | Nehrme et al. (2018) |
| iPSCs             | Human              | LHX6    |                                                   | Yuan et al. (2018) |
| iPSCs             | Human              | Zeb1    |                                                   | Jiang et al. (2018) |
| iPSCs             | Human              | Ngn2    |                                                   | Meijer et al. (2019) |
| iPSCs             | Human              | NGN2 or ASCL1 + DLX2 | Rhee et al. (2019) |
| iPSCs             | Human              | Ngn2    |                                                   | Nickolls et al. (2020) |
| iPSCs             | Mouse              | Nurr1   |                                                   | Soldati et al. (2012) |
| iPSCs             | Mouse              | Foxa2   |                                                   | Kittappa et al. (2007) |
| iPSCs             | Rat                | Nurr1   |                                                   | Sakurada et al. (1999) |

*Continued*
TABLE 1 | Continued

| Desired cell type | Starting cell type | Species | Transcription factor used for forward programming | References |
|------------------|-------------------|---------|-----------------------------------------------|------------|
| NPCs             | Rat               | Nurr1   | Nurr1 or Ascl1+Nurr1 or Nurr1+Ng1 or Nurr1+Ng2 or Nurr1+Shh or Nurr1+Bcl-XL or Nurr1+Bcl-XL+Shh | (10) Kim et al. (2003) |
| NPCs             | Rat               | Dmrt5   | Nurr1 or Nurr1 or Nurr1+Shh or Nurr1+Bcl-XL or Nurr1+Bcl-XL+Shh | (11) Park et al. (2006) |
| ESC-derived NPCs | Mouse             | Lmx1a   | Lmx1a or En1 or Otx2 or Lmx1a+En1 or Lmx1a+Otx2 or Lmx1a+En1+Otx2 or Lmx1a+En1+Otx2+Foxa2 | (12) Friling et al. (2009) |
| ESC-derived NPCs | Mouse             | Bcl-XL  | Nurr1 or Nurr1 or Nurr1+Shh or Nurr1+Bcl-XL or Nurr1+Bcl-XL+Shh | (13) Bae et al. (2009) |
| PSC-derived NPCs | Human             | PBX1    | PBX1 or PBX1+Ascl1 or PBX1+Ascl1+Mef2 | (14) Gennet et al. (2011) |
| ESC-derived NPCs | Human             | ASCL1, FOXA2, LMX1A, NGN2, NURR1, OTX2 and PITX3 (alone or in combination) | (15) Andersson et al. (2006) |
| ESC-derived NPCs | Human             | LMX1A   | LMX1A or LMX1A+En1 or LMX1A+Otx2 or LMX1A+Otx2+En1 or LMX1A+Otx2+Foxa2 | (16) Panman et al. (2011) |
| ESC-derived NPCs | Human             | mAscl1+mNurr1+mLmx1a | Neurod1, Neurod2, Neurod3 | (7) Theka et al. (2013) |
| PSC-derived NPCs | Human             | ATOH1   | ATOH1 or ATOH1+Ascl1 or ATOH1+Ascl1+Mef2 | (17) Sagal et al. (2014) |
| iPSCs            | Mouse             | Ngn2    | Ngn2+Is1+Lhx3 or Ngn2+Is1+Phox2a | (18) Xue et al. (2019) |
| ESCs-derived NPCs| Human             | NGN2+1SL1+LHX3 | Neurod1, Neurod2, Neurod3 | (19) Faedo et al. (2017) |
| iPSCs            | Mouse             | Phox2b  | Phox2b or Olig2 | (20) Panman et al. (2011) |
| IPSCs            | Human             | Atsh    | Atsh or Atsh+Ascl1 or Atsh+Ascl1+Mef2 | (21) Hester et al. (2011) |
| iPSCs            | Human             | NGN2    | NGN2 or NGN2+ISL1 or NGN2+ISL1+PHOX2A | (22) Mazzoni et al. (2013) |
| ESCs-derived NPCs| Human             | NGN1    | NGN1+NGN2 or NGN1+NGN2+ISL1 or NGN1+NGN2+ISL1+PHOX2A | (23) Busskamp et al. (2014) |
| iPSCs            | Human             | NGN1+ISL1+LHX3 | Neurod1, Neurod2, Neurod3 | (24) Goparaju et al. (2017) |
| iPSCs            | Human             | NGN2+ISL1+LHX3 or NGN2+ISL1+PHOX2A | Neurod1, Neurod2, Neurod3 | (25) Goto et al. (2017) |
| iPSCs            | Human             | NGN2+BRN3A | Neurod1, Neurod2, Neurod3 | (26) De Santis et al. (2018) |
| iPSCs            | Human             | NGN1+BRN3A | Neurod1, Neurod2, Neurod3 | (27) Schrenk-Siemens et al. (2015) |
| iPSCs            | Human             | NGN2    | Neurod1, Neurod2, Neurod3 | (28) Nickolai et al. (2020) |
| iPSCs            | Human             | NGN1    | Neurod1, Neurod2, Neurod3 | (29) Song et al. (2017) |
| iPSCs            | Human             | Ngn1    | Neurod1, Neurod2, Neurod3 | (30) Panman et al. (2011) |

Numbers in superscript relate to citations in Figure 2.

(Thoma et al., 2012). The first ground-breaking proof that NGN2 has the same effect in human PSCs was – again – provided by the groups of Marius Wernig and Thomas Südhof in 2013. The authors demonstrated that forward programming human PSCs with NGN2 reproducibly yields neurons with almost 100% purity within 2 weeks, and as was observed in mouse cells, these neurons do not only acquire neuronal-like electrophysiological properties but are also capable of functionally integrating into synaptic networks with cortical mouse neurons. Notably, the authors further reported that overexpressing the bHLH TF NEUROD1 can instruct neuronal differentiation from human PSCs, too (Zhang et al., 2013). Interestingly, already in 2001, O’Shea (2001) had investigated the neurogenic effect of Neurod TFs by overexpressing Neurod1, Neurod2, and Neurod3 in mouse ESCs and found that all three Neurods suffice to induce immature neuronal-like cells within 72 h.

More recently, other groups have corroborated the finding that NGN2 overexpression suffices to forward program human PSCs to neurons expressing MAP2 and NEUN within 2 to 10 days of differentiation (Rubio et al., 2016; Goparaju et al., 2017; Matsushita et al., 2017; Pawlowski et al., 2017). Neuronal differentiation can be further accelerated by combined...
overexpression of NGN1 and NGN2, and in this case, 90% of all cells were found to express MAP2 and the synapse marker synapsin already at day 4 of differentiation. However, additional morphological, transcriptomic, and functional analyses indicate that a majority of the obtained neurons at this early time point are still immature and not yet fully developed (Busskamp et al., 2014). Yet, several labs including our own have revealed that co-culturing NGN2-neurons with glial cells significantly facilitates maturation (Zhang et al., 2013; Busskamp et al., 2014; Meijer et al., 2019; Rhee et al., 2019), and when cultured under appropriate conditions, neurons derived by forward programming can be utilized for sophisticated electrophysiological analyses: Cultured on glia microdots, single forward programmed NGN2-neurons form an autaptic system by making synapses onto themselves, which can be used for studying functional features such as synaptic transmission and short-term plasticity (Meijer et al., 2019; Rhee et al., 2019), and networks of forward programmed neurons cultured on multielectrode arrays have also been employed for functional analyses (Frega et al., 2017; Nehme et al., 2018).

Mechanisms Underlying bHLH Transcription Factor-Mediated Forward Programming

bHLH TFs are named after their common protein structure motif consisting of two α-helices mediating dimerization and a basic domain, which binds to E-box motifs with the consensus sequence CANNTG. The group of bHLH TFs is subdivided according to their ubiquitous versus tissue-specific expression profile, and neural bHLH TFs are further grouped into the achaete-scute complex and atonal gene families (for further details see review by Dennis et al., 2019). First hints as to why bHLH TFs might be able to orchestrate neuronal fate acquisition were obtained from NPC-to-neuron differentiation paradigms: Ngn1, for instance, specifically binds to E-box motifs at neuronal genes in rat NPCs, acting as a direct transcriptional activator (Sun et al., 2001). In human PSCs, the TFs NGN1, NGN2 and NGN3 seem to even cross-activate each other and induce common pro-neural down-stream targets including other bHLH TFs such as NEUROD1, NEUROD2 and NEUROD4 (Busskamp et al., 2014; Goparaju et al., 2017; Xue et al., 2019). Such a synergism might not be restricted to the group of NGNs, since the bHLH TF ATOH1 has been shown to induce both, NGN2 and NEUROD1 in human PSCs, and was thus used for forward programming of human PSCs into neurons (Sagal et al., 2014; Xue et al., 2019). These observations might indicate that one common mechanism underlying neuronal forward programming of PSCs with bHLH TFs is the activation of a whole network of cross-regulated bHLH TFs, including the induction of more down-stream Neurod TFs. In line with this hypothesis, no difference was reported comparing the neuronal induction potency of NGN1, NGN2, NGN3, NEUROD1, and NEUROD2 in human ESCs (Matsushita et al., 2017).

In order to elucidate the mechanism by which combined NGN1 and NGN2 overexpression drives neuronal fate acquisition of human iPSCs more in depth, Busskamp et al. (2014) performed a comprehensive set of experiments dissecting mRNA and miRNA regulation kinetics during the early phase of neural induction. A mRNA network analysis revealed that during the first 4 days of differentiation, destabilization of the pluripotency network is initiated by decreasing SOX2, NANOG, and OCT4 levels, and genes associated with an NPC stage and the gene ontology term ‘regulation of neurogenesis’ such as NOTCH1, DLL1, DLL4, HESS, FABP7, and NTN1 are temporarily upregulated. This phase of NPC marker induction is very brief, though (as was also observed by Zhang et al., 2013), resulting in a significant downregulation of cell cycle-related genes by day 4, which suggests that PSC-derived cells only traverse a short progenitor-like phase during forward programming. In line with this, neuron-associated genes such as POUSF2 (also known as BRN2), ZEB1, ISL1, TLX3, and POU4F1 (also known as BRN3a) are upregulated already in this early phase of reprogramming, whilst inhibitors of neurogenesis as for instance REST and HES1 are repressed. Concomitant with the dynamics of mRNA regulation, the expression of the pluripotency-associated miRNA cluster 302/367 decreases, whereas the abundance of neuronal miRNAs such as miR124, miR96, and miR9 increases upon differentiation (Busskamp et al., 2014).

The molecular consequences of Neurod1 induction were explicitly investigated by Vijay Tiwari’s group in mouse ESCs: Neurod1 overexpression influences chromatin accessibility at its target sites by reducing repressive H3K27me3 marks, increasing H3K27ac and recruiting RNA polymerase II. Hence, during the first 24 h of differentiation, the fraction of enhancer and promotor regions directly bound by Neurod1 probably accounts for approximately 25% of all upregulated genes identified by RNA sequencing. Interestingly, upregulated genes are exclusively enriched for neurogenesis-associated gene ontology terms, and consequently, after 48 h, and even in the presence of the pluripotency-promoting factor Lif, Tubb3 expression is induced. Even transient Neurod1 expression for as short as 48 h suffices to stably remodel the epigenetic and transcriptional landscape at Neurod1 targets, which later drive neuronal differentiation of ESCs even in the absence of Neurod1 (Pataskar et al., 2016). Altogether, these data indicate that activation of the bHLH TF Neurod1 might represent one of the crucial entry points for neural fate acquisition in forward programming paradigms.

Neuronal Forward Programming Factors Beyond the bHLH Family

Neuronal specification from diverse NPC populations can be driven by pro-neural, non-bHLH TFs such as Pax6 (Hack et al., 2004), Brn4 (Shi et al., 2010; Tan et al., 2010) and members of the Sox family of TFs (Kan et al., 2004; Braccioli et al., 2018). Furthermore, overexpression of Dlk1 in mouse and human ESC-derived NPCs facilitates neural specification by promoting cell cycle exit via reduction of Notch, and modulation of BMP signaling (Surmacz et al., 2012). Finally, decreasing REST signaling in human NPC lines induces neurogenesis, too (Huang et al., 2011), and this can most likely be attributed to REST’s function as a transcriptional repressor of neuronal
genes such as Tubb3 (Greenway et al., 2007) and Neurod2 (DeWald et al., 2011).

Considering these observations, it is not surprising that non-bHLH TFs have also been implemented in forward programming of PSCs. Yamamizu et al. (2013) for instance, identified that doxycycline-mediated induction of Nr2f1 or Smad7 can instruct neuronal differentiation of mouse ESCs. Liu et al. (2018) further performed a comprehensive CRISPR activation screen in mouse ESCs and revealed that besides the bHLH TFs Ngn1 and Tcf15, also non-bHLH TFs such as Brn2, Foxo1, Ezh2 and Zeb1 have neurogenic potential. Zeb1 and Zeb2, for instance, are homologous TFs and downstream effectors of the IncRNA-1604, which regulates neural differentiation by competitive binding with miRNA-200c in mouse ESCs (Weng et al., 2018), and ZEB1 is also induced after combined overexpression of Ngn1 and Ngn2 in human iPSCs (Busskamp et al., 2014). Yet, at least for Zeb1 it was shown by other groups that its neuron-promoting effect is comparably weak. When overexpressed in human ESCs, ZEB1 does not immediately decrease pluripotency markers OCT4, NANOG, and SOX2, and most cells are negative for the early neuronal marker TUBB3 up until day 25 of differentiation (Jiang et al., 2018). Since it was demonstrated that Zeb2 overexpression decreases Ngn2 expression in embryonic midbrain cells and a dopaminergic cell line (Yang et al., 2018), a negative correlation between these two TFs might account for the observed weak pro-neuronic effect. Conversely, forward programming by Ezh2 induction results in the formation of electrophysiological active and synapse-forming neurons, which is comparable to the effect of Ngn1-mediated forward programming. The pro-neurogenic action of Ezh2 might most likely be due to its inhibitory effect on endodermal and mesodermal lineage-associated genes (Liu et al., 2018), which is in line with the fact that the methyltransferase Ezh2 is a core component of the PRC2 complex and involved in transcriptional repression.

In sum, these studies hint at some common mechanisms underlying TF-driven specification of NPCs and PSCs into neurons, which include (i) exit of the original cell fate, (ii) repression of alternative lineage decisions, and (iii) activation of a pro-neuronal transcriptional program.

**Forward Programming Into Clinically Relevant Neuronal Subtypes**

When thinking of forward programming as a tool to produce neural cell types for brain repair, it is particularly relevant to thoroughly characterize the exact phenotype of the obtained cells. Already Serre et al. (2012) noted that the four different bHLH TFs Ngn1, Ngn2, Ngn3, and Ascl1 had slightly varying effects on neuronal subtype specification from human primary cortical NPCs, although cultures generally consisted of a mixed population of GABAergic, cholinergic, serotonergic, adrenergic, and MNs (Serre et al., 2012). This observation is in line with other reports demonstrating divergent effects for different bHLH TFs on neuronal subtype derivation: Overexpression of Ascl1 induces a GABAergic bias in neuronal cultures differentiating from neurospheres isolated from both human fetal cortex and mesencephalon (Kim et al., 2009), whereas Ngn2 overexpression in human iPSC-derived NPCs (Ho et al., 2016) and PSCs (Zhang et al., 2013; Nehme et al., 2018; Meijer et al., 2019; Rhee et al., 2019; Nickolls et al., 2020) leads to the derivation of mostly glutamatergic neurons.

**Cortical Glutamatergic and Forebrain GABAergic Neurons**

The results of multiple independent studies indicate that glutamatergic neurons derived by overexpression of Ngn2 adopt a telencephalic fate characterized by the expression of cortical layer II/III markers such as FOXG1, BRN2, SATB2, and CUX1 (Zhang et al., 2013; Frega et al., 2017; Wang et al., 2017; Nehme et al., 2018; Meijer et al., 2019). However, there are reports indicating that forward programming with a combination of Ngn1 and Ngn2 results in neurons co-expressing vGLUT1 and ChAT (Busskamp et al., 2014). Similarly, mRNA-driven combinatorial overexpression of Ngn1, Ngn2, Ngn3, NEUROD1, and NEUROD2 in human PSCs gives rise to a population of remarkably pure cholinergic MNs (Goparaju et al., 2017), indicating that Ngn2 can, in particular in combination with additional TFs and morphogens, instruct other fates than glutamatergic neurons (see also section ‘Motor and Sensory Neurons’). Ascl1 – which is expressed in more ventral regions of the telencephalon in vivo (Casarosa et al., 1999; Fode et al., 2000) – is alone insufficient to consistently give rise to homogenous cultures of only one specific neuronal subtype and instead results in mixed cultures of MNs, dopaminergic and GABAergic neurons (Yamamizu et al., 2013). However, in a landmark study, Yang et al. (2017) demonstrated that overexpression of Ascl1 in combination with DLX2, a downstream effector of Ascl1, is able to direct human PSCs into remarkably pure cultures of telencephalic forebrain GABAergic neurons. Sun et al. (2016) used a combination of Ascl1 and DLX2 with LHX6 and a synthetic cluster of miRNA-9/9* and miRNA-124 (miR9/9*-124), and found that the induced GABAergic neurons express markers reminiscent of derivatives of the medial ganglionic eminence, but not alternative birthplaces such as the lateral ganglionic eminence, caudal ganglionic eminence or the preoptic area. As somatostatin- and parvalbumin-positive inhibitory interneurons appear to play a particular role in several neurological and neuropsychiatric diseases, the generation of these subtypes would be highly desirable. Colasante et al. (2015) reported that combinatorial overexpression of the five TFs FOXG1, SOX2, ASCL1, DLX5, and LHX6 in human iPSCs gives rise to highly enriched cultures of parvalbumin-expressing inhibitory neurons. Yuan et al. (2018) explored overexpression of LHX6 alone and found that 80% of the human PSC-derived neurons were GABAergic, with a fraction of 21% and 29% of the TUBB3-positive neurons co-expressing parvalbumin and somatostatin, respectively. As with forward programmed excitatory neurons, functional maturation of induced GABAergic neurons can be promoted by co-culture with primary rodent glia (Sun et al., 2016). Interestingly, this process can also be promoted by co-culture with Ngn2-forward programmed...
excitatory neurons (Yang et al., 2017) – an observation which could suggest that utmost functionality can only be achieved in the context of a heterogenous synaptic network as encountered in vivo.

### Midbrain Dopaminergic Neurons

Representing a prime target of PD, midbrain dopamine neurons are a particularly attractive donor cell population for neural repair. However, the efficacy of neuror regeneration seems to heavily depend on the fidelity of neuronal subtype specification. This was recently exemplified by Kirkeby et al. (2017), who revealed that the purity of dopaminergic cell preparations (i.e., the ratio of caudal ventral mesencephalic dopaminergic neurons versus neurons of the diencephalic subthalamic nucleus) is predictive for successful dopaminergic specification and symptom amelioration after transplantation into a mouse model of PD. Although potent extrinsic factor-guided protocols for the derivation of dopaminergic neurons from PSCs exist (Kriks et al., 2011; Kirkeby et al., 2012), there is a necessity to further fine-tune cell fate subspecification. This was nicely illustrated by La Manno et al. (2016), who profiled the developing mouse and human midbrain using single cell RNA sequencing, and delineated multiple molecularly diverse NPC populations and several distinct classes of mature dopaminergic neurons in the midbrain of both species. Notably, the authors compared transcriptomic signatures of human PSC-derived dopaminergic neurons with their in vivo counterparts and found that although the morphogen-driven dopaminergic differentiation recapitulated key developmental stages of embryonic dopaminergic lineage specification, the gene expression profile of in vitro generated populations still differed from that of native midbrain dopamine neurons. The question remains whether forward programming can further improve the authenticity of specialized dopaminergic neuron subpopulations.

Already beginning in the end of last century, several labs reported that overexpression of the mesencephalic TF Nurr1 in primary adult rat hippocampal NPCs (Sakurada et al., 1999) and primary embryonic rat cortical NPCs (Kim et al., 2003; Park et al., 2006; Bae et al., 2009) promotes the generation of a midbrain dopamine neuron-like phenotype. A similar effect was communicated for primary mouse NPCs isolated from the ganglionic eminence and midbrain as well as mouse ESC-derived NPCs, whereas NPCs from embryonic cortex and spinal cord as well as adult NPCs from the subventricular zone seemed resistant to the pro-dopaminergic patterning effect of Nurr1 (Soldati et al., 2012). Other midbrain-specific TFs that were tested for their potency to instruct dopaminergic fates include (i) Foxa2, which, when overexpressed in mouse primary midbrain-derived and ESC-derived NPCs, was found to boost the derivation of TH-positive neurons (Kittappa et al., 2007), (ii) Lmx1a, which efficiently specifies murine Shh- and Fgf8-treated (Andersson et al., 2006; Panman et al., 2011) as well as human ESC-derived NPCs toward a dopaminergic fate (Friling et al., 2009), and in combination with Foxa2 and Barhl1 drives dopaminergic differentiation from Fgf8- and CHIR99021-exposed murine ESC-derived NPCs (Kee et al., 2017), (iii) En1 and (iv) Otx2, which were reported to drive dopaminergic differentiation of murine NPCs alone, each in combination with Lmx1a, or as a 3 TF cocktail (Panman et al., 2011), (v) Dmr5, which does not increase overall neuronal yield after being overexpressed in mouse ESC-derived dopaminergic NPCs but specifically induces an increase of certain midbrain dopaminergic markers on RNA level (Gennet et al., 2011), and (vi) PBX1, which appears to cooperate with NURR1 promoting dopaminergic specification from human PSC-derived NPCs (Villaescusa et al., 2016). Another good example is the recently published study by Azimi et al. (2018), who used magnetically guided mRNA spot delivery to screen single TFs and TF combinations for their capacity to commit human ESC-derived NPCs toward a dopaminergic fate, and revealed that transfection of FOXA2, LMX1A, and PITX3 mRNA results in an increased yield of TH-positive neurons. Combinatorial delivery of these 3 TFs at their respective most effective stage results in almost 68% of TH- and MAP2-double-positive cells (Azimi et al., 2018).

Nurr1 was also the first TF explored in the context of forward programming PSCs toward a dopaminergic fate, and its overexpression in mouse ESCs causes a substantial increase in the number of TH-expressing neurons (Chung et al., 2002; Kim et al., 2002). Exposure to the morphogens Shh and Fgf8 further increases the yield of TH-expressing neurons after Nurr1 overexpression with enrichment in the order of 60% to 80% (Chung et al., 2002; Kim et al., 2002), and enhances the release of dopamine after induced depolarization (Kim et al., 2002). The combination of Nurr1 with other TFs (such as Gpx1), morphogens (as for instance RA) and chemicals (e.g., β-boswellic acid) was reported to boost the yield of dopaminergic neurons, too (Abasi et al., 2012). Especially the combined expression of Nurr1 and Pitx3 was shown to be beneficial for the derivation of dopaminergic neurons from mouse PSCs (Martinat et al., 2006; Salemi et al., 2016). Whereas these TFs alone are sufficient to induce markers expressed early in dopaminergic development such as TH and Aldh2, it is only upon co-expression that they synergistically induce more advanced markers such as Dat and Tyrp1 (Martinat et al., 2006). In this co-expression paradigm, too, addition of Shh and Fgf8 increased the induced secretion of dopamine from these cells (Salemi et al., 2016). Notably, and in contrast to overexpression of Nurr1 alone (Kim et al., 2002), co-expression of Nurr1 and Pitx3 (along with exposure to Shh and Fgf8) prevents the derivation of ‘contaminating’ cell fates such as serotonergic or GABAergic neurons (Martinat et al., 2006).
in particular. In their study, lentiviral overexpression of this TF cocktail in human iPSCs gave rise to homogenous neuronal cultures expressing a wide range of proteins associated to the dopaminergic lineage such as TH, DAT, ALDH1A1, and GIRQ2. Resulting neurons exhibited neuron-like electrophysiological properties and were able to spontaneously release dopamine after 3 weeks of differentiation. However, although the number of TH- and TUBB3-co-expressing cells doubled when applying the TF cocktail (Theka et al., 2013), the overall yield of TH-expressing neurons remained lower as compared to the yield after overexpression of LMX1A alone (Sánchez-Danés et al., 2012). This difference might be attributable to the lack of additional patterning molecules such as SHH and FGF8 in the medium used by Vania Broccoli’s group, and/or shorter differentiation times till analysis, and thus warrants further studies on forward programming approaches combining neurogenic and regionalizing TFs.

Finally, it is worth mentioning that the bHLH TF ATOH1 is itself able to induce dopaminergic neurons from human PSCs, especially when combined with exposure to SHH and FGF8b. In combination with these morphogens, ATOH1 overexpression yields up to 82% TH-expressing neurons. In addition to TH, FOXA2, NURR1, LMX1A, DAT, VMAT2, and OTX2 are significantly upregulated during ATOH1-driven differentiation. Characterization of the growth factor-treated, ATOH1-overexpressing neuronal cultures on a functional level demonstrated that these neurons possess electrophysiological properties similar to primary rat midbrain dopaminergic neurons and exhibit dopamine release after electrical stimulation at day 36 of differentiation, suggesting actual functionality (Sagal et al., 2014). Very recently, this approach was further improved by establishing a protocol based on combined ATOH1 and NGN2 overexpression in human iPSCs via repetitive mRNA transfections (Xue et al., 2019).

Medium Spiny Neurons

Another neuronal subtype of particular biomedical interest are MSNs, a GABAergic population abundantly found in the striatum and most prominently affected by HD. In human ESC-derived NPCs treated with SHH and the WNT inhibitor DKK1, overexpression of GSX2 and EBF1, two TFs essential for the development of striatal interneurons, actively suppresses the expression of the medial ganglionic eminence progenitor markers PAX6 and NKX2.1 and drives cell cycle exit. After 60 days of long-term differentiation, overexpression of both TFs finally results in MSN progenitor cells expressing ISL1- and CTIP2; by day 80, 38.8% of all cells co-express the MN markers DARPP32 and CTIP2 (Faedo et al., 2017). However, whether or not this TF combination would be capable of directly specifying undifferentiated PSCs to MSNs merits further investigation.

Motor and Sensory Neurons

Motor neuron development and specification in vivo is relatively well studied (see reviews by Jessell, 2000 and Briscoe and Ericson, 2001), and this knowledge was efficiently exploited for studies focusing on the in vitro generation of enriched MN populations, which are affected by degenerative diseases such as amyotrophic lateral sclerosis. Hester et al. (2011) for instance, successfully combined NGN2-driven differentiation of SHH- and RA-treated human PSC-derived NPCs with overexpression of the MN lineage-specific markers ISL1 and LHX3 yielding 60% cells co-expressing the MN markers ISL1 and ChAT at day 13 of differentiation. In 2013, the group of Hynek Wichterle demonstrated that overexpression of this TF combination can also successfully specify the differentiation of mouse ESCs into spinal MNs directly, whereas cranial MNs can be obtained by replacing Lhx3 by Phox2a in this TF cocktail. A systematic comparison of these two different TF combinations by gene array analysis revealed a sharp decrease of pluripotency-associated genes Oct4 and Nanog and an upregulation of pan-MN markers such as Isl1, Ebf1 and Ebf3 as well as the VACHT in both paradigms, whereas upregulation of Tbx20, Phox2a, Phox2b, Rg4, and Gal was only detected in neurons subjected to forward programming with Phox2a. The results of this study further indicate that these divergent outcomes are obtained because Isl1 is recruited to different genomic sites when co-expressed with Ngdn in combination with either Lhx3 or Phox2a. Yet, both MN subpopulations become electrophysiologically functional and capable of forming cholinergic synapses after maturation on cortical mouse astrocytes (Mazzoni et al., 2013). A few years later, Goto et al. (2017) verified that Sendai virus-mediated overexpression of the TF cocktail NGN2, ISL1 and LHX3 in human PSCs, too, promotes the expression of MN markers. More specifically, only the full TF cocktail and the 2-factor combination of NGN2 and LHX3 but neither NGN2 in conjunction with ISL1 nor any of the single TFs resulted in MN derivation. Notably, after 3 weeks of differentiation NGN2/ISL1/LHX3-overexpressing neurons were electrophysiologically active and formed neuromuscular junctions with cultured myocytes (Goto et al., 2017). De Santis et al. (2018) expressed both TF combinations identified by Hynek Wichterle’s group (NGN2/ISL1/LHX3 and NGN2/ISL1/PHOX2A) in human iPSCs via Piggy-bac transposable vectors. Concordant with the previous results, iPSCs downregulated the pluripotency marker NANOG and upregulated pan-MN genes such as TUBB3, ISL1, and ChAT within the first 3 days of differentiation. By day 5, HB9 expression was increased when LHX3 was co-expressed, whereas PHOX2B, TRX20, and RG4 were detected upon PHOX2A overexpression. Finally, the authors of this study functionally characterized the cranial MNs obtained after 12 to 13 days of NGN2/ISL1/PHOX2A overexpression and observed that these cells were capable of firing action potentials upon current stimulation, and almost half of all analyzed cells even displayed spontaneous glutamatergic postsynaptic currents (De Santis et al., 2018).

Whilst these studies utilized joined overexpression of the neurogenic TF Ngdn with MN lineage-associated TFs, Goparaju et al. (2017) investigated whether overexpression of generic neurogenic TFs can induce specified neuronal subtypes when combined with fate-modulating extrinsic factors. Indeed, they found that overexpression of NGN1, NGN2, NGN3, NEUROD1, and NEUROD2 in human PSCs combined with RA, forskolin and dual SMAD inhibition via SB431542 and dorsomorphin yields highly pure neuronal cultures expressing the MN markers.
HB9, ISL1, and ChAT (Goparaju et al., 2017). Interestingly, the combination of NGN2 overexpression with forskolin and dorsomorphin treatment has been described to even convert human fibroblasts into cholinergic MNs (Liu et al., 2013).

On the other hand, Panman et al. (2011) revealed that overexpression of the MN-associated TFs Phox2b and Olig2 in mouse ESC-derived, posterior-ventral NPCs suffices to specify visceral and somatic MNs, respectively. Further dissecting the role of Phox2 TFs in segregating MNs from other populations of hindbrain neurons, Mong et al. (2013) overexpressed either Phox2a or Phox2b in Nestin-expressing ESC-derived NPCs. Although the expression of both TFs largely overlaps in vivo, the sequence of their expression is known to be important for the specification of different neuronal subtypes: Phox2a precedes Phox2b induction during the development of noradrenergic (Pattyn et al., 2000) and midbrain MNs (Pattyn et al., 1997), whereas in hindbrain visceral MNs, Phox2b is induced before Phox2a (see review by Brunet and Pattyn, 2002). Knock-out studies further showed that although Phox2b expression can compensate for effects caused by Phox2a-knock-out in noradrenergic neurons of the locus coeruleus, it does not suffice to rescue the loss of MNs in the midbrain (Coppola et al., 2005). Vice versa, Phox2a cannot completely compensate for Phox2b loss during the development of noradrenergic neurons and visceral MNs (Coppola et al., 2005). Concordant with these findings, overexpression of both Phox2 TFs in mouse and human ESC-derived NPCs upregulated the expression of visceral MN markers as for instance Isl1, Nkx6.2, Thx2, and Tbx20 when combined with the morphogens Fgf8 and Shh. Conversely, combining Phox2b but not Phox2a overexpression with Bmp7 and Fgf8 treatment increased the expression of genes characteristic for noradrenergic neurons such as Tjap2a, Dbh, Tlx3, and Net (Mong et al., 2013).

Very recently, the group of Carsten Bönningmann published a protocol to derive sensory neurons from human iPSCs via forward programming. The authors demonstrated that even in the absence of neuronal lineage-promoting medium conditions, doxycycline-induced expression of NGN2 and BRN3A from the absence of neuronal lineage-promoting medium conditions, forward programming. The authors demonstrated that even in a protocol to derive sensory neurons from human iPSCs via induction of Stat3 by overexpression of Rnf20 (Liang et al., 2018). Overexpression of the TF Emx2 in mouse cortical NPCs regulates Efg and Fgf signaling, which are crucial for maintaining the pool of proliferating astrocyte progenitors (Falcone et al., 2015).

In a landmark study, Canals et al. (2018) lentivirally overexpressed the NFI TF family member NFIB alone or in combination with SOX9 in human PSCs. In this paradigm, PSCs differentiate into mature, post-mitotic astrocytes expressing markers such as GFAP, S100, VIM, ALDH1L1, and GLAST within 21 days of differentiation. At this differentiation stage, astrocytes further contain glycogen-positive granules comparable to primary astrocytes. Functional assessments of these forward programmed astrocytes between days 14 and 21 of differentiation revealed that the derived cells exhibit typical characteristics of human adult astrocytes such as generation and propagation of spontaneous calcium waves, glutamate uptake, responsiveness to ATP and inflammatory stimuli such as IL-1β, the ability to form functional gap junctions with other astrocytes and the potency to promote synaptogenesis in a co-culture system with iPS-derived neurons (Canals et al., 2018).

Independent of and almost at the same time as the report by Canals et al. (2018), the lab of Su-Chun Zhang published a protocol to derive functional astrocytes from human PSCs by doxycycline-inducible expression of NFI-A, another NFI TF family member, via CRISPR/Cas9-mediated targeting of the human AAVS1 genomic safe harbor locus. By overexpressing SOX9 in addition to NFIA, and combining this forward
programming protocol with a conventional morphogen-driven astrocyte differentiation paradigm, the efficiency of astrocyte generation was significantly increased so that finally around 70% of all cells co-expressed the astrocyte markers GFAP and S100β at day 52 of differentiation. Similar to the astrocytes derived by Canals et al. (2018), their cells could propagate calcium waves, take up free glutamate from the culture medium, and positively regulate NFIB levels, has been reported to promote the fast generation of astrocytes in combination with glia-promoting, LIF-containing medium. Continued overexpression of this TF, however, inhibited astrogensis from NPCs, probably by inducing premature G1 cell cycle arrest (Tchieu et al., 2019). Surprisingly, overexpression of the long non-coding RNA lnc-158, which is an endogenous antisense RNA of NFIB and positively regulates NFIB levels, has been reported to promote the differentiation of primary mouse NPCs into oligodendrocytes instead of astrocytes (Li Y. et al., 2018).

**Promoting Oligodendrogenesis by Transcription Factor Overexpression**

Wang et al. (2014) screened 5 TFs (NKX2.2, OLIG2, PRRX1, ASCL1, and SOX10) known to be associated with oligodendrocyte lineage commitment and analyzed their potency to induce OPC markers in primary human NPCs. Whilst all examined TFs repressed astrocytic genes, NKX2.2 and especially ASCL1 induced the expression of neuronal genes in addition to oligodendrocyte lineage commitment and analyzed their potency to induce OPC markers in primary human NPCs. Gene set enrichment analyses of RNA sequencing data further revealed that only SOX10 overexpression induced genes expressed in both primary mouse and human OPcs, whereas ASCL1-induced OPCs expressed markers resembling mouse but not human OPC fate. The authors further demonstrated the superiority of SOX10-induced OPCs by the fact that only this population could be cultured in vitro for several passages whilst maintaining its oligodendrocyte differentiation potential (Wang et al., 2014). In line with the results of Wang et al. (2014) are various other reports from different groups demonstrating the oligodendrocyte-promoting

**TABLE 2 | Transcription factors used for promoting glial differentiation of neural precursor cells and pluripotent stem cells in vitro.**

| Derived cell type | Starting cell type | Species | Transcription factor used for forward programming | References |
|-------------------|--------------------|---------|-----------------------------------------------|------------|
| Astrocytes        | NPCs               | Mouse   | Emx2                                          | Falcone et al. (2015) |
|                   | NPCs               | Human   | Rtn120                                         | Liang et al. (2018) |
|                   | iPSC-derived NPCs  | Human   | NFIA                                          | (17) Tchieu et al. (2019) |
|                   | PSCs               | Human   | NFIB or NFIB+SOX9                              | (18) Canals et al. (2018) |
|                   | PSCs               | Human   | NFIA or NFIA+SOX9                              | (16) Li X. et al. (2018) |
| Oligodendrocytes  | NPCs               | Mouse   | Olig1                                         | Balasubramaniyan et al. (2004) |
|                   | NPCs               | Mouse   | Olig1 or Olig2 or Nkx2.2                      | (19) Copray et al. (2006) |
|                   | NPCs               | Mouse   | Ascl1 or Olig2 or Nkx2.2 or Ascl1+Olig2 or    | Sugimori et al. (2008) |
|                   | NPCs               | Mouse   | Nkx2.2AS                                      | Tochitani and Hayashizaki (2008) |
|                   | NPCs               | Mouse   | Olig1 or Olig2                                | Maire et al. (2010) |
|                   | NPCs               | Mouse   | Ascl1 or Olig2 or Sox10                        | Braun et al. (2015) |
|                   | NPCs               | Mouse   | Sox10                                         | (24) Matjusaitis et al. (2019) |
|                   | NPCs               | Mouse   | Lnc-158                                       | Li Y. et al. (2018) |
|                   | NPCs               | Human   | OLIG1 or OLIG2+OLIG1+OLIG2                    | (21) Hwang et al. (2009) |
|                   | NPCs               | Human   | OLIG2                                         | (20) Maire et al. (2009) |
|                   | NPCs               | Human   | ASCL1 or Nkx2.2 or OLIG2 or PRRX1 or SOX10    | (22) Wang et al. (2014) |
|                   | iPSC-derived NPCs  | Human   | OLIG1 or OLIG2 or OLIG1+OLIG2                 | Li et al. (2017) |
|                   | PSC-derived NPCs   | Human   | SOX10 or Nkx6.2+OLIG2+SOX10                   | (23) Ehrlich et al. (2017) |
|                   | iPSCs              | Human   | OLIG2+SOX10                                   | (25) García-León et al. (2018) |
|                   | PSCs               | Human   | SOX10 or OLIG2+SOX10                         | Li P. et al. (2016) |
|                   |                    |         |                                               | Pavlovski et al. (2017) |

Numbers in superscript relate to citations in Figure 2.
effects of Ascl1 in combination with Olig2 or Nkx2.2 (Sugimori et al., 2008), as well as Ascl1 (Braun et al., 2015), Olig1/2 (Balasubramaniyan et al., 2004; Copray et al., 2006; Sugimori et al., 2008; Hwang et al., 2009; Maire et al., 2009, 2010; Braun et al., 2015; Li et al., 2017), Nkx2.2 (Copray et al., 2006; Sugimori et al., 2008; Tochitani and Hayashizaki, 2008) and Sox10 (Braun et al., 2015; Ehrlich et al., 2017; García-León et al., 2018; Matjusaitis et al., 2019) alone. Interestingly, overexpression of Ascl1 in vivo has also been shown to coax endogenous hippocampal NPCs into an oligodendroglial, myelination-competent phenotype (Jessberger et al., 2008; Braun et al., 2015).

Ehrlich et al. (2017) demonstrated that overexpression of SOX10 alone can induce oligodendrocyte differentiation of cultured human iPSC-derived NPCs. Yet, oligodendrocyte derivation is more efficient when SOX10 is overexpressed in combination with OLG2 and NKKX6.2. With this improved protocol, around 60% to 80% of all cells stain positive for GALC and O4 at day 28 of differentiation and O4-enriched oligodendrocytes exhibit the capability to myelinate iPSC-derived neurons after 3 weeks of in vitro co-cultivation (Ehrlich et al., 2017). One year after the report of Ehrlich et al. (2017), also the group of Catherine Verfaillie published a protocol to derive oligodendrocytes from human PSC-derived NPCs by lentiviral SOX10 overexpression: García-León et al. (2018) performed RNA sequencing analysis of purified O4-positive cells at day 22 of differentiation, demonstrating that their protocol gives rise to oligodendrocytes that highly resemble intermediate to mature primary human brain-derived oligodendrocytes. Moreover, purified O4-positive oligodendrocytes were able to myelinate human iPSC-derived neurons after 20 days of co-culture. Finally, García-León et al. (2018) created a stable human ESC-line with doxycycline-inducible expression of SOX10 from the endogenous AAVS1 locus and demonstrated that this approach successfully generates mature oligodendrocytes when transgene expression is induced at the NPC stage. Noteworthy, however, doxycycline-induced expression of SOX10 at the ESC stage was insufficient to give rise to MBP-expressing oligodendrocytes (García-León et al., 2018).

Whereas these studies have identified multiple routes to promote oligodendrocyte differentiation from an NPC stage, direct TF-driven specification of PSCs toward the oligodendrocyte lineage has remained more challenging to achieve. Li P. et al. (2016) reported that combining a multi-step growth factor-based differentiation protocol with SOX10 and OLG2 overexpression in human iPSCs results in cultures consisting of around 40% O4-positive oligodendrocytes after 4 weeks of differentiation. However, when co-culturing SOX10/OLG2-induced OPCs with embryonic primary rat cortical neurons, only around 5% of all cells stained positive for O4 at day 14 of co-culture and just 0.5% of all rat axons co-labeled with processes extending from human forward programmed oligodendrocytes (Li P. et al., 2016). One year later, the group of Mark Kotter published a highly controlled SOX10 and OLG2-driven forward programming protocol for the derivation of oligodendrocytes from human PSCs, which is based on inducible transgene overexpression by dual genomic safe harbor targeting (i.e., targeting the doxycycline-responsive transcriptional activator to the ROSA26 and the tetracycline-responsive element-regulated transgenes of interest to the AAVS1 locus). Interestingly, using this system, the authors could generate proliferative OPCs, which terminally differentiated into almost pure cultures of oligodendroglial cells expressing characteristic markers such as CNP and PLP upon mitogen withdrawal (Pawlowski et al., 2017).

It will be interesting to investigate whether TFs and TF combinations explored in the context of fibroblast-to-glia transdifferentiation can be exploited for forward programming of PSCs. For instance, direct cell fate conversion of rodent fibroblasts into OPCs was achieved by combined overexpression of the TFs Sox10 and Olig2 with either Nkx6.2 (Najm et al., 2013; Matjusaitis et al., 2019) or Zfp536 (Yang et al., 2013). Similarly, myelination-competent Schwann cells can be derived from mouse and human fibroblasts via the combined overexpression of Sox10 and Krox20 (Mazzara et al., 2017; Sowa et al., 2017) and have been shown to accelerate nerve regeneration and motor recovery after transplantation into mice with sciatic nerve transection (Sowa et al., 2017).

Taken together, the results of these studies unpin the potency of some TFs and/or TF combinations for oligodendrocyte specification. Yet, the efficient direct specification of oligodendrocytes form a PSC state deserves further attention. In addition to TFs, miRNAs could be supportive in this process. The miRNAs miR-219 and miR-338 were shown to promote oligodendrocyte maturation by targeting inhibitors of oligodendrogenesis such as Sox6 and Hes5, as well as promoters of neurogenesis as for instance Neurod1, Isl1, Otx2, and Zfp238/RPS5 (Zhao et al., 2010).

**IN VIVO APPLICATION OF FORWARD PROGRAMMED CELLS: INSIGHTS FROM TRANSPANTATION STUDIES**

As a proof-of-concept for the general applicability of forward programmed cells for neuroregenerative approaches, these cells can be transplanted into healthy animals and monitored for graft survival, maturation and integration (Figure 2). Along this line, Zhang et al. (2013) demonstrated that 6 weeks after transplanting human immature neurons (7 days after infecting ESCs with a lentivirus encoding for NGN2) into the mouse striatum, the grafted cells adopted a neuronal phenotype exhibiting dendritic arborizations, axonal outgrowth and electrophysiological functionality, and received inhibitory synaptic input from host striatal interneurons (Zhang et al., 2013). Yuan et al. (2018) transplanted human PSC-derived NPCs, forward programmed by LHX6 overexpression, into the ventral mouse forebrain. Surprisingly, the authors observed that the number of GABAergic interneurons overall was not significantly increased in the doxycycline-induced, forward programmed grafts as compared to uninduced control transplants, and LHX6-overexpressing as well as uninduced control grafts differentiated into all four interneuron subtypes. Still, the forward programmed neurons exhibited spontaneous...
FIGURE 2 | In vivo applications of cell types derived by forward programming. Numbers in superscript relate to references cited in Tables 1, 2.

| Donor cell                           | Transplant model                                    | Readout                                                                 |
|--------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------|
| Generic neuronal progenitors          | Unlesioned mouse or traumatically lesioned rat brain | Survival\(^1\), cell type-specific marker expression\(^2\)               |
| Forebrain glutamatergic progenitors   | Unlesioned mouse brain                               | Cell type-specific marker expression\(^5\), electrophysiology\(^7\)       |
| Forebrain GABAergic progenitors       | Unlesioned mouse brain                               | Survival\(^6\), cell type-specific marker expression\(^8\), electrophysiology\(^9\), cortical layer integration\(^6\) |
| Midbrain dopaminergic progenitors     | Unlesioned mouse brain or 6-hydroxydopamine-lesioned mouse or rat brain | Survival\(^7\), cell type-specific marker expression\(^10\), electrophysiology\(^9\), behaviour\(^1\) |
| Medium spiny neuron progenitors       | Quinolinic acid-lesioned rat brain                   | Survival\(^4\), cell type-specific marker expression\(^11\), substantia nigra innervation\(^1\) |
| Motor neuron progenitors              | Unlesioned chicken cervical and brachial tube         | Cell type-specific marker expression\(^12\), site-specific integration of cranial and spinal MNs\(^1\) |
| Astrocyte progenitor cells            | Unlesioned mouse brain                               | Cell type-specific marker expression\(^13\), migration\(^1\), interaction with blood vessels\(^1\), gap junction formation with endogenous astrocytes\(^1\) |
| Oligodendrocyte progenitor cells      | Spinal cord contusion rat model, Cuprizone mouse model or Shiverer mouse mutants | Survival\(^14\), cell type-specific marker expression\(^15\), migration\(^1\), myelination\(^1\), behaviour\(^1\) |

Electrophysiological activity and postsynaptic currents reflecting mostly inhibitory GABAergic input (Yuan et al., 2018), demonstrating that forward programmed neurons can – in principal – exhibit proper functionality upon grafting. This notion is substantiated by reports of several other groups: For instance, 14-day-old neurons, derived from human PSCs by ASCL1- and DLX2-overexpression, survive transplantation into the subventricular zone and cerebral cortex of neonatal mice and mature into GABAergic neurons within 3 months post transplantation (Yang et al., 2017), and neurons derived from human PSCs by combined ASCL1, DLX2 and LHX6 overexpression mature into GABAergic neurons in vivo, too (Sun et al., 2016). Notably, 2 months after grafting, these GABAergic neurons had functionally integrated into cortical layers V and VI, exhibiting repetitive action potential firing and receiving synaptic input from host neurons (Sun et al., 2016). In an elegant study by the group of Hynek Wichterle, MNs were programmed by overexpressing Ngn2 and Isl1 in combination with either Lhx3 or Phox2a in mouse ESCs, and the resulting cells were grafted into the cervical and brachial tube of chicken embryos 2 days after transgene induction. Already 2 days after transplantation, the grafted cells had spatially segregated and exhibited axonal projections concordant with their MN subclass identity: Like spinal MNs, Ngn2/Is11/Lhx3-overexpressing cells accumulated in axial and limb nerve branches and exhibited substantial axonal outgrowth from the ventral root of the spinal cord, whereas Ngn2/Is11/Phox2a-derived neurons accumulated in the lateral spinal cord and projected axons toward the spinal accessory nerve resembling cranial MNs (Mazzoni et al., 2013).

Whilst transplantation into unlesioned healthy recipients can be a highly useful tool to assess the in vivo differentiation and function of forward programmed neurons, studies in the context of a disease model can provide information on their regenerative capacity. First milestones to use forward programmed neurons for experimental neuroregeneration were already achieved as early as 2002, when Kim et al. (2002) transplanted Nurr1-overexpressing mouse ESC-derived neurons in the striatum of 6-OHDA-lesioned rats, an animal model of PD. 4 to 8 weeks post transplantation, the majority of transplanted cells expressed the dopaminergic marker TH, and 5 out of 6 grafts exhibited spontaneous postsynaptic currents. Most importantly, the authors demonstrated that animals transplanted with Nurr1-overexpressing neurons showed improved behavioral recovery compared to animals receiving sham injections or grafts of wild-type cells (Kim et al., 2002). Martinat et al. (2006) reported a
few years later that Nurr1/Pitx3-induced mouse and human ESC-derived NPCs grafted into the striatum of 6-OHDA-lesioned mice resulted in a significant reduction in apomorphine-induced rotation behavior compared to the transplantation of control vector-transduced cells. However, further immunohistochemical analyses of the grafts revealed that in their setting, neurons retained an immature morphology with only a minority of them expressing TH (Martinat et al., 2006). In accordance with this finding, Theka et al. (2013) more recently showed that 12 days after transplanting immature dopaminergic neurons (8 days post inducing ASCL1, NURR1 and LMX1A in human iPSCs) 4 out of 6 grafts survived, and only a fraction of the surviving cells displayed neuronal morphologies and expression of TH (Theka et al., 2013). Similar results were reported by Kim et al. (2003), who demonstrated that although transplantation of rat wild-type midbrain NPCs improves behavior of 6-OHDA-lesioned rats, transplantation of Nurr1-overexpressing midbrain or cortical NPCs does not, presumably because Nurr1-NPC grafts contained fewer TH-positive neurons which additionally exhibited immature morphologies (Kim et al., 2003). Whilst these findings were confirmed by Park et al. (2006), their study further revealed that 8 weeks after transplanting rat NPCs overexpressing a combination of Nurr1, Ascl1 and Shh or Nurr1, Bcl-XL and Shh, dopaminergic specification and dopamine levels are increased and motor deficits decreased compared to transplantation of NPCs overexpressing Nurr1 alone (Park et al., 2006). In a study by Friling et al. (2009) only 50% of all grafts survived after transplanting mouse Lmx1a-overexpressing ESC-derived NPCs into 6-OHDA-lesioned rats. In these grafts, the majority of the transplanted cells co-expressed the dopaminergic markers TH, Pitx3, Enl1/2, Lmx1a and Vmat, and even non-overlapping positivity for Girk2 and calbindin, indicating generation of both, substantia nigra A9 neurons and ventral tegmental area A10 dopaminergic neurons (Friling et al., 2009). Lastly, NPCs derived from ESCs via forward programming with Lmx1a differentiate into TH, DAT and Girk2-expressing dopaminergic neurons in vivo, too (Sánchez-Danés et al., 2012).

In addition to PD, HD is intensely explored as a candidate disease for neural cell replacement. Since striatal MSNs are the main target of the disease, fast and efficient in vitro generation of MSNs is a key prerequisite for a cell therapeutic approach. Faedo et al. (2017) grafted human ESC-derived NPCs carrying inducible GSX2 and EBF1 transgenes into the quinolinic acid-lesioned striatum and observed that 2 months after transplantation, these NPCs had differentiated into GABAergic neurons expressing the striatal MSN markers CTIP2 and DARPP32 and extending projections toward the substantia nigra (Faedo et al., 2017). However, comparable to what has been observed after transplantation of forward programmed dopaminergic neurons (Theka et al., 2013), the number of CTIP2-positive human neurons was not different in GSX2/EBF1-overexpressing transplants versus uninduced control grafts (Faedo et al., 2017). It remains to be investigated whether or not MSNs directly forward programmed from the PSC stage would survive and integrate upon transplantation.

Forward programmed glial cells might be valuable for neuroregenerative interventions, too. For astrocytes, however, there are only few published reports about the general feasibility of grafting these cells. Yet, these reports demonstrated that forward programmed astrocytes maintain their cellular identity up to 3 months after grafting (Li Y. et al., 2018a; Tchieu et al., 2019) and exhibit astrocyte-specific traits in vivo such as their affinity to blood vessels and the formation of functional gap junctions with host astrocytes (Canals et al., 2018). For oligodendrocytes, Copray et al. (2006) reported that Olig2-expressing mouse NPCs grafted into the demyelinated mouse striatum differentiate into mature MBP-positive oligodendrocytes engaging in remyelination (Copray et al., 2006). In line with this, Hwang et al. (2009) demonstrated that Olig2-expressing NPCs survive transplantation into contused spinal cord better than wild-type NPCs and exhibit increased proliferation and migration into white matter tissue, where they efficiently differentiate into MBP-positive oligodendrocytes promoting myelination. Potentially due to this pro-myelinating effect, transplantation of Olig2-NPCs improves locomotion after contusive injury compared to sham injection or transplantation of wild-type NPCs (Hwang et al., 2009). Also in Shiverer/Rag mice, which are used as models for myelination disorders, NPCs overexpressing Olig2 (Maire et al., 2009) or SOX10 (Wang et al., 2014; Matjuszaitis et al., 2019) have been shown to differentiate into MBP-positive oligodendrocytes exhibiting ensheathment of host axons. Transplantation of more mature O4-positive oligodendrocytes, which were derived from human NPCs by SOX10 overexpression, promotes myelination in brain slices of Shiverer/Rag mice as well (Garcia-León et al., 2018). In an elegant study, Ehrlich et al. (2017), demonstrated that magnetic activated cell sorting (MACS)-purified O4-positive oligodendrocytes (14 days after induction of the TFs SOX10, Olig2, and NKX6.2 in human NPCs) not only promote the formation of normally compacted MBP-positive sheaths with nodal structures around host neurons 16 weeks post transplantation but are also capable of remyelination after neurotransplantation in Shiverer/Rag mice treated with the membrane-dissolving chemical lysophosphatidyl-choline, which induces completely demyelinated lesions in white matter tissue (Ehrlich et al., 2017). However, since all of these transplantation studies were conducted with OPCs or oligodendrocytes derived by TF overexpression in NPCs, there is no proof so far that oligodendrocytes forward programmed from PSCs can survive neurotransplantation. This certainly merits further investigations, since OPCs directly converted from somatic fibroblasts were demonstrated to be capable of differentiating into myelinating oligodendroglial cells after transplantation into the brain of Shiverer/Rag mice, too (Najm et al., 2013; Yang et al., 2013).

**FORWARD PROGRAMMING OF PSCs VERSUS PRIMARY CELL FATE CONVERSION**

Since forward programming of PSCs can be regarded as a fallout of the technological advances of somatic cell reprogramming into iPSC and direct interconversion of somatic cells within
and across germ layers, it is interesting to reflect on the commonalities and differences of these in vitro approaches. From a mechanistic point of view, direct cell fate conversion can be segregated into two different phases, which has been nicely deciphered in several milestone publications in the context of transdifferentiating fibroblasts into neurons via Ascl1, Brn2, and Myt11 overexpression (Vierbuchlen et al., 2010; Wapinski et al., 2013; Treutlein et al., 2016; Mall et al., 2017). Here, the fibroblast’s chromatin landscape has to be remodeled first in order to become permissive to TF binding at neuron-specific genes. This chromatin opening can be mediated by small molecules acting as epigenetic modifiers, or induced by cell type-specific pioneer TFs, which – by definition – are able to bind to and open up closed chromatin. Second, following the necessary epigenetic rearrangements, the transcriptional landscape has to be modulated in order to activate neuronal genes and inhibit the acquisition of alternative fates, including the repression of fibroblast-specific transcriptional signatures. Notably, many principles regulating the acquisition of a new cell fate during transdifferentiation seem to apply to forward programming, too. Aydin et al. (2019) recently analyzed how Ngn2 and Ascl1 specify mouse ESCs into neurons and demonstrated that both bHLH TFs act as neuronal pioneer TFs binding to genes which are in closed chromatin states in ESCs. By this, Ngn2 and Ascl1 induce and recruit secondary pro-neural TFs such as Brn2, thereby promoting the acquisition and stabilization of a neuronal fate. Interestingly, and in accordance with other publications, Aydin et al. (2019) further report that despite the high similarity of the mechanistic action of these two TFs, Ngn2 and Ascl1 induce quite distinct neuronal programs as the binding patterns of both TFs in ESCs are largely divergent.

Although the general principles underlying forward programming and direct cell fate conversion seem to be quite similar, there are some differences which need to be highlighted (Table 3). First, the epigenetic hurdles that have to be overcome for the proper activation of an alternative transcriptional program seem to be lower in PSCs than in terminally differentiated somatic cells (in particular in the case of a trans-germ layer conversion). Thus, although Ascl1, for instance, is sufficient to specify PSCs into neurons, it is comparatively inefficient to convert fibroblasts into authentic iNs when overexpressed alone (Liu et al., 2018), and Ngn2 or Neurods, which are commonly used in forward programming paradigms, seem almost incapable of converting fibroblasts into iNs (Chanda et al., 2014; Liu et al., 2018). Second, from a time perspective, the derivation of neuronal cells from somatic cells is faster via the direct conversion route compared to forward programming via the iPSC stage: In this scenario, transdifferentiation is a one-step-procedure, whereas for forward programming, somatic cells have to be first reprogrammed into iPSCs before they can be differentiated into the desired somatic cell type by TF overexpression. However, due to the intermediate pluripotent stage, the forward programming route is scalable at the iPSC stage and can give rise to highly homogeneous cell batches. Notably, it is still not completely resolved whether forward programming of PSCs involves a stable NPC intermediate, since upregulation of NPC-associated

| Table 3 | Comparative summary of key features important for cell fate engineering. |
|---------|---------------------------------------------------------------|
|         | Forward programming | Direct cell fate conversion |
| Epigenetic barriers for reprogramming | Low | High |
| Scalability | High | Limited depending on proliferative potential of converted product |
| Degree of standardization that can be reached | High | Limited depending on proliferative potential of converted product |
| Preservation of somatic and age memory | Low | Potentially high |
| Possible translation into clinical applications | Indirect (via transplantation) | Direct and indirect (via in situ conversion and transplantation of converted cells) |

markers was reported to be very short-lasting (Zhang et al., 2013; Busskamp et al., 2014). Likewise, transient activation of an NPC-like transcriptional program was recently described in the context of direct pericyte-to-neuron conversion (Karow et al., 2018). Interestingly, however, single cell-RNA sequencing of neural cultures derived from human PSCs via Ngn2 overexpression recently indicated that even after culturing these cells in neuronal differentiation-promoting medium on mouse glia, a significant fraction of cells can remain in an NPC-like stage resisting neuronal maturation (Nehme et al., 2018). Third, in contrast to forward programming from homogenous iPSC batches, every iN represents a single, post-mitotic direct cell fate conversion event. This means that transdifferentiation-derived cultures represent a mosaic of a vast number of single conversion events, which severely limits the degree of standardization that can be reached with an iN approach. Furthermore, since neurons are post-mitotic, the cell yield of an iN conversion is always limited by (i) the number of starting cells and (ii) the efficiency of the direct conversion approach. However, these drawbacks do not equally apply to all transdifferentiation paradigms. Instead of deriving terminally differentiated iNs, direct cell fate conversion can be used to generate induced neural stem cells (iNSCs; Han et al., 2012; Ring et al., 2012; Shahbazi et al., 2016; Sheng et al., 2018) induced neuronal-like NPCs (iNPCs; Giorgetti et al., 2012), or even iNPCs which are already primed to differentiate toward a specific neuronal subtype such as dopaminergic neurons (Tian et al., 2015). As these cells are stably self-renewing, especially iNSC cultures are almost as scalable and homogeneous as PSCs. Yet, direct conversion into iNSC/iNPCs has the drawback that, as with forward programming, it has to be followed up by a subsequent terminal differentiation step. Here, it is tempting to consider translating previous approaches on facilitating the differentiation of primary or PSC-derived NPCs by TF overexpression to iNSCs/iNPCs. A key issue in all these scenarios remains cell type authenticity, which can be compromised if the converted cells retain a significant degree of epigenetic and transcriptomic memory relating to the fate but also the age of the cell of origin. This memory seems to be largely maintained in fibroblast-derived iNs of different donor ages (Mertens et al., 2015; Yang et al., 2015; Huh et al., 2016; Tang et al., 2017; Kim et al., 2018), whereas it is almost completely reset in iPSCs.
being fast enough to be able to provide autologous cells from
Forward programming comes with the significant benefit of
cell type subspecification, authenticity,
APPLICATION
conversion of somatic cells.
In situ an inducing stimulus and can thus be activated to convert
in vivo cells that are already engineered to overexpress specific TFs upon
in vivo the mouse brain (Matsuda et al., 2019). A special variant of
originate from the yolk sac, are amenable to neuronal conversion
in vivo in 6-OHDA-lesioned PD mice (Rivetti Di Val Cervo et al., 2017).
importantly, the group of Magdalena Götz recently revealed that
transmission and improves spontaneous motor behavior deficits
recent reviews (Heinrich et al., 2015; Grealiish et al., 2016; Srivastava and DeWitt, 2016; Barker et al., 2018; Flitsch and Brüstle, 2019; Pesaresi et al., 2019), it might eventually provide a
short-cut for brain repair bypassing a transplantation step and is
thus worth mentioning here. Several studies have shown that such
a transdifferentiation step can be triggered in vivo by the direct
administration of reprogramming cues like TFs and/or miRNAs
to resident rodent brain cells such as astrocytes (Buffo et al.,
2005; Kronenberg et al., 2010; Guo et al., 2014; Faiz et al., 2015;
Ghasemi-Kasman et al., 2015; Liu et al., 2015; Torper et al., 2015;
Gascón et al., 2016) and NG2-positive glial cells (Guo et al., 2014;
Heinrich et al., 2014; Torper et al., 2015; Gascón et al., 2016). In
this context, the group of Ernest Arenas demonstrated that even
the in vivo conversion of mouse astrocytes into clinically
relevant neuronal subtypes such as midbrain dopaminergic
neurons is feasible. The authors overexpressed a TF cocktail
comprising Ascl1, Lmx1a, Neurod1, and miRNA-218 in mouse
brain astrocytes by stereotactic lentivirus injection and revealed
that this does not only successfully elicit transdifferentiation but
finally also corrects basal and postsynaptic deficits in dopamine
transmission and improves spontaneous motor behavior deficits
in 6-OHDA-lesioned PD mice (Rivetti Di Val Cervo et al., 2017).
Importantly, the group of Magdalena Götz recently revealed that
in vivo conversion of mouse cortical astrocytes into neurons
can preserve region-and even layer-specific identities (Mattugini
et al., 2019). This study also impressively underpins the relevance
and potential impact of subspecification within the glial lineage.
Lastly, it has recently been shown that in vivo cell fate conversion
can even be extended beyond germ layer boundaries: Matsuda
et al. (2019) reported that brain-resident microglia, which
originate from the yolk sac, are amenable to neuronal conversion
in the mouse brain (Matsuda et al., 2019). A special variant of
the in vivo conversion concept is the idea to transplant somatic
cells that are already engineered to overexpress specific TFs upon
an inducing stimulus and can thus be activated to convert in situ
(Torper et al., 2013). Taken together, these reports underline the
enormous biomedical potential of both, direct in vitro and in vivo
conversion of somatic cells.

CHALLENGES FOR FUTURE CLINICAL APPLICATION

Cell Type Subspecification, Authenticity, and Maturity

Forward programming comes with the significant benefit of
being fast enough to be able to provide autologous cells from
human patients for cell replacement therapies. However, on the
benchwork side, one significant limitation of some currently
available forward programming protocols is the reduced purity of
the obtained cultures, especially when it comes to deriving highly
specified neuronal subtypes. In some cases, subspecification might be augmented by the use of morphogens and small
molecules. On the one hand, these molecules can help to
properly regionalize (intermediate) NPC stages, as they might
provide additional phenotype-instructing differentiation cues,
which could otherwise only be delivered by combining several
TFs upstream of the lineage-relevant signaling pathways. This
was nicely exemplified by the group of Johan Ericson and
Thomas Perlmann, who showed that overexpression of Lmx1a
in ESC-derived mouse NPCs suffices to instruct dopaminergic
neuron differentiation when combined with Shh and Fgf8
treatment, whereas caudalized NPCs only adopt a dopaminergic
phenotype if the three midbrain-associated TFs Lmx1a, En1,
and Otx2 are overexpressed in combination (Panman et al.,
2011). On the other hand, small molecules might act as
epigentic modifiers and facilitate forward programming by
either re-activating lineage-instructive genes, which are in an
unfavorable epigenetic state or even completely silenced in
PSCs, or by repressing alternative lineages (similar to the
mode of action that has been described for the TF EZH2; Liu
et al., 2018). In direct cell fate conversion, for instance, iN
derivation from human fibroblasts via NGN2 overexpression is
only successful if combined with the treatment with two small
molecules, namely forskolin and dorsomorphin, which modulate
chromatin accessibility at NGN2 target sites (Liu et al., 2013;
Smith et al., 2016).

Another challenge for the clinical application of forward
programmed cells might be the degree of cellular authenticity
and maturity that can be achieved. One way to improve neuronal
maturation in vitro is to co-culture forward programmed neurons
with glial cells. Notably, the species from which the glial cells
are retrieved might influence their maturation-promoting effect:
In a recent study, culturing human glutamatergic neurons
and GABAergic neurons did not show this selective response to glial
co-culture (Rhee et al., 2019), and whether or not these effects also
apply to forward programmed neurons is still to be determined.
Further studies are also required in order to clarify to
what extent forward programmed neurons resemble their
physiological in vivo counterparts. For example, in a recent study
4-week-old NGN2-forward programmed human neurons grown
in an autopseit setting displayed surprising morphological and
functional properties, including systematic multi-peak excitatory
postsynaptic currents originating from neurons possessing
multiple axons, which were evident in about 25% of all cells
analyzed (Meijer et al., 2019; Rhee et al., 2019). Increased
axonal lengths and small diameters contributed to the observed
phenomenon, and further resulted in extended synaptic delays
as compared to mouse forebrain cortical neurons. Moreover,
detection of a slow component contributing to these unusual
(Polo et al., 2010; Lo Sardo et al., 2017; Olova et al., 2019).
Recently, directly converted INSCs were shown to largely reset
age-associated cellular signatures, too (Sheng et al., 2018).

Prospects of Direct Cell Fate Conversion
in vivo

Direct cell fate conversion cannot only be achieved in vitro but
also directly in vivo. While this concept is distinct from classic
forward programming and has received its own coverage in
several recent reviews (Heinrich et al., 2015; Grealiish et al., 2016;
Srivastava and DeWitt, 2016; Barker et al., 2018; Flitsch and
Brüstle, 2019; Pesaresi et al., 2019), it might eventually provide a
short-cut for brain repair bypassing a transplantation step and is
thus worth mentioning here. Several studies have shown that such
a transdifferentiation step can be triggered in vivo by the direct
administration of reprogramming cues like TFs and/or miRNAs
to resident rodent brain cells such as astrocytes (Buffo et al.,
2005; Kronenberg et al., 2010; Guo et al., 2014; Faiz et al., 2015;
Ghasemi-Kasman et al., 2015; Liu et al., 2015; Torper et al., 2015;
Gascón et al., 2016) and NG2-positive glial cells (Guo et al., 2014;
Heinrich et al., 2014; Torper et al., 2015; Gascón et al., 2016). In
this context, the group of Ernest Arenas demonstrated that even
the in vivo conversion of mouse astrocytes into clinically
relevant neuronal subtypes such as midbrain dopaminergic
neurons is feasible. The authors overexpressed a TF cocktail
comprising Ascl1, Lmx1a, Neurod1, and miRNA-218 in mouse
brain astrocytes by stereotactic lentivirus injection and revealed
that this does not only successfully elicit transdifferentiation but
finally also corrects basal and postsynaptic deficits in dopamine
transmission and improves spontaneous motor behavior deficits
in 6-OHDA-lesioned PD mice (Rivetti Di Val Cervo et al., 2017).
Importantly, the group of Magdalena Götz recently revealed that
in vivo conversion of mouse cortical astrocytes into neurons
can preserve region-and even layer-specific identities (Mattugini
et al., 2019). This study also impressively underpins the relevance
and potential impact of subspecification within the glial lineage.
Lastly, it has recently been shown that in vivo cell fate conversion
can even be extended beyond germ layer boundaries: Matsuda
et al. (2019) reported that brain-resident microglia, which
originate from the yolk sac, are amenable to neuronal conversion
in the mouse brain (Matsuda et al., 2019). A special variant of
the in vivo conversion concept is the idea to transplant somatic
cells that are already engineered to overexpress specific TFs upon
an inducing stimulus and can thus be activated to convert in situ
(Torper et al., 2013). Taken together, these reports underline the
enormous biomedical potential of both, direct in vitro and in vivo
conversion of somatic cells.
electrophysiological kinetics indicated that the NGN2-neurons possess the ability to co-release GABA and glutamate from the same synapse (Rhee et al., 2019). Although there are neurons in vivo, which grow multiple axons and/or co-release different neurotransmitters from the same synapse, these findings deserve further attention.

Transgene Delivery, Stability of Programmed Phenotypes and Safety

From a translational perspective, extrinsic factor-driven protocols, such as the delivery of differentiation cues by growth factors, morphogens and/or small molecules but also TF-based approaches employing mRNAs or proteins rather than integrating constructs might be easier to pass regulatory hurdles associated with the implementation of clinical trials. So far, however, most TF-based approaches have been relying on genetic modification of the target cell either by the use of integrating viruses or gene editing techniques such as CRISPR/Cas9. A main advantage of integrating a fate-instructing TF by techniques such as TALENs or CRISPR/Cas9 is better control on the integration site. Accordingly, some studies successfully integrated the forward programming-conveying TFs in the human genomic safe harbor AAVS1 locus with high precision (Wang et al., 2017; García-León et al., 2018; Li Y. et al., 2018a; Meijer et al., 2019; Rhee et al., 2019). While integration-free methods such as mRNA (Goparaju et al., 2017; Matsushita et al., 2017; Xue et al., 2019) or protein delivery (Robinson et al., 2016) are appealing, they come with their own pros and cons. For instance, mRNAs are rapidly translated but subsequently also timely degraded after entering the target cells, and significant protocol adaptations might be necessary to enable efficient transfection at all (Xue et al., 2019). Protein delivery, on the other hand, is technically challenging but also the only technique that circumvents potential post-translational regulation (Robinson et al., 2016).

Another challenge is the maintenance of inducible transgene activation in the grafted cells until the point where the cellular phenotype of the transplanted cells becomes stable and transgene-independent. In principle, this could be tackled by grafting cells at later stages of in vitro specification. However, advanced pre-differentiation is typically associated with decreased survival and integration of the grafted cells. Thus, it might be beneficial to implement modalities for continuous delivery of TFs, e.g., by repetitive virus injection or slow-release depots in form of scaffolds binding or encapsulating fate-specifying proteins such as TFs and/or morphogens (see review by Bruggeman et al., 2019). Prolonged provision of fate-specifying factors beyond the timepoint of transplantation might also enhance the in vivo stability of neuronal subtype identities: Although there are TF-based protocols available to produce quite specific neuronal subtypes in vitro, the results of several studies suggest that TF-mediated acquisition and maintenance of subtype specification might be less efficient in transplanted neurons compared to a pure in vitro scenario (Martinat et al., 2006; Theka et al., 2013; Faedo et al., 2017; Yuan et al., 2018).

Another issue to be tackled when it comes to clinical transplantation is the fact that although grafting NPCs is more efficient than transplantation of terminally differentiated mature cells – a notion particularly relevant for neurons (for a more comprehensive commentary, see Björklund and Lindvall, 2000) – transplantation of still immature cells such as differentiating PSCs and NPCs can increase the risk of uncontrolled overgrowth (Friling et al., 2009). While growth factor-based protocols might be more vulnerable to this complication, teratoma formation after transplantation has also been observed in the context of TF overexpression paradigms (Martinat et al., 2006; Friling et al., 2009).

CONCLUDING REMARKS

TF overexpression in NPCs and TF-based forward programming of PSCs are valuable techniques to derive specialized and comparably mature neural cells within short time frames and thus provide powerful alternatives to classic growth factor-mediated PSC differentiation and direct (somatic) cell fate conversion. Besides generating precious insights into how cell fates are established and controlled by transcriptional and epigenetic regulation, one major asset of these approaches is that they can provide new donor sources for brain repair. Yet, a number of issues need to be addressed more deeply before forward programming can be implemented in a clinical setting.

AUTHOR CONTRIBUTIONS

LF, KL, and OB contributed to the writing and editing of the manuscript.

FUNDING

This work was supported by grants from the European Union’s FP7 Program (FP7-HEALTH-F4-2013-602278-Neurostemcellrepair) and Horizon 2020 Program (H2020-667301-COSYN), the German Federal Ministry of Education and Research (01EK1603A-Neuro2D3), the ERA-Net Neuron Program (01EW1812A-TREAT-SNGAP), and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, United States (R01NS100514). The content is solely the responsibility of the authors and does not necessarily represent the official views of these funding agencies.

ACKNOWLEDGMENTS

All figures were created with the BioRender.com online tool.
REFERENCES

Abasi, M., Massumi, M., Riazì, G., and Amini, H. (2012). The synergistic effect of beta-boswellic acid and Nur71 overexpression on dopaminergic programming of antioxidant glutathione peroxidase-1-expressing murine embryonic stem cells. *Neuroscience* 222, 404–416. doi: 10.1016/j.neuroscience.2012.07.099

Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Aleksenko, Z., Robert, B., et al. (2006). Identification of intrinsic determinants of midbrain dopamine neurons. *Cell 124*, 393–405. doi: 10.1016/j.cell.2005.10.037

Aydin, B., Kakumanu, A., Rossillo, M., Moreno-Estellés, M., Garipler, G., Ringstad, N., et al. (2019). Pronuclear factors Ascl1 and Neurog2 contribute to neuronal subtype identities by establishing distinct chromatin landscapes. *Nat. Neurosci.* 22, 897–908. doi: 10.1038/s41593-019-0399-y

Azimi, S. M., Sheridan, S. D., Ghannad-Rezaie, M., Eimon, P. M., and Yanik, M. F. (2018). Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery. *eLife* 7:e31922. doi: 10.7554/elife.31922

Bae, E. J., Lee, H. S., Park, C. H., and Lee, S. H. (2009). Orphan nuclear receptor Nur1 induces neuron differentiation from embryonic cortical progenitor cells via an extrinsic paracrine mechanism. *FEBS Lett.* 583, 1505–1510. doi: 10.1016/j.febslet.2009.04.004

Balasubramaniyan, V., Timmer, N., Kust, B., Boddeke, E., and Copray, S. (2004). Transient expression of Olig1 initiates the differentiation of neural stem cells into oligodendrocyte progenitor cells. *Stem Cells* 2, 812–822. doi: 10.1634/stemcells.22-6-878

Barretto, N., Zhang, H., Powell, S. K., Fernando, M. B., Zhang, S., Flaherty, E. K., et al. (2020). ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. *J. Neurosci. Methods* 334:108548. doi: 10.1016/j.jneumeth.2019.108548

Bernaer, B., Costa, M. R., Koch, U., Schroeder, T., Sutor, B., Grothe, B., et al. (2007). Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. *J. Neurosci.* 27, 8654–8664. doi: 10.1523/JNEUROSCI.1615-07.2007

Björklund, A., and Lindvall, O. (2000). Cell replacement therapies for central neurons. *Cell* 124, 693–696. doi: 10.1016/s0092-8674(00)01072-0

Braccioli, L., Vervoort, S. J., Puma, G., Nijboer, C. H., and Coffer, P. J. (2018). SOX10 single transcription factor-based fast and efficient generation of mouse oligodendrocytes enhances remyelination in the adult brain after injury. *Cell Rep.* 22, 897–908. doi: 10.1016/j.celrep.2018.02.021

Briscoe, J., and Ericson, J. (2001). Specification of neuronal fates in the ventral neuroectoderm. *Cell* 107, 613–623. doi: 10.1016/s0092-8674(01)00300-4

Buffo, A., Vosko, M. R., Ertürk, D., Hamann, G. F., Jucker, M., Rowitch, D., et al. (2019). Generation of functional forebrain GABAergic interneurons by direct genetic reprogramming. *Cell Stem Cell* 17, 719–734. doi: 10.1016/j.stem.2015.09.002

Casarosa, S., Fode, C., and Guillomet, F. (1999). Mash1 regulates neurogenesis in the ventral telencephalon. *Development* 126, 523–534. doi: 10.1101/gad.01020117

Chanda, S., Ang, C. E., Davila, J., Pak, C. M., Mall, M., Lee, Q. Y., et al. (2014). Generation of induced neuronal cells by the single reprogramming factor Ascl1. *Stem Cell Rep.* 3, 282–296. doi: 10.1016/j.stemcr.2014.05.020

Coppola, E., Pattyn, A., Guthrie, S. C., Goridis, C., and Studer, M. (2005). Reciprocal gene replacements reveal unique functions for Phox2 genes during neural differentiation. *EMBO J.* 24, 4392–4403. doi: 10.1038/sj/emboj.7600897

Correa-Cerro, L. S., Piao, Y., Sharon, A. A., Nishiyama, A., Cadet, J. S., Yu, X., et al. (2011). Generation of mouse ES cell lines engineered for the forced induction of transcription factors. *Sci. Rep.* 1:167. doi: 10.1038/srep00167

Davis, R. L., Weintraub, H., and Lassar, A. B. (1987). Expression of a single transfectected cDNA converts fibroblasts to myoblasts. *Cell* 51, 987–1000. doi: 10.1016/0092-8674(87)90585-X

De Santis, R., Gane, A., Pansu, F., Di Angelantonio, S., and Rosa, A. (2018). Direct conversion of human pluripotent stem cells into cranial motor neurons using a piggyBac vector. *Cell Stem Cell* 29, 189–196. doi: 10.1016/j.stem.2018.04.012

Dennis, D. J., Han, S., and Schuurmans, C. (2019). BHLH transcription factors in neural development, disease, and reprogramming. *Brain Res.* 1705, 48–65. doi: 10.1016/j.brainsres.2018.03.013

DeWeald, L. E., Rodrigues, J. P., and Levine, J. M. (2011). The RE1 binding protein REST regulates oligodendrocyte differentiation. *J. Neurosci.* 31, 3470–3483. doi: 10.1523/NEUROSCI.2768-10.2011

Ehrlich, M., Mozafari, S., Glatza, M., Starost, L., Velychko, S., Hallmann, A. L., et al. (2017). Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. *Proc. Natl. Acad. Sci. U.S.A.* 114, E2243–E2252. doi: 10.1073/pnas.1614412114

Fode, C., Ma, Q., Casarosa, S., Ang, S. L., Anderson, D. J., and Guillomet, F. (2000). A role for neural differentiation genes in specifying the dorsoventral identity of telencephalic neurons. *Genes Dev.* 14, 67–80. doi: 10.1101/gad.14.1.67

Frega, M., van Gestel, S. H. C., Linda, K., van der Raadt, J., Keller, J., Van Rhijn, J. R., et al. (2017). Rapid neuronal differentiation of induced pluripotent stem cells for measuring network activity on micro-electrode arrays. *J. Vis. Exp.* 119:54900. doi: 10.3791/54900

Frisch, M., Filippis, C., Granzotto, M., and Mallamaci, A. (2015). Eomes expression levels in NSCs modulate astrogensis rates by regulating Egr1 and Fog9. *GLIA* 63, 412–422. doi: 10.1002/glia.22761

Flitsch, L. J., and Brüstle, O. (2019). Evolving principles underlying neural lineage conversion and their relevance for biomedical translation. *F1000Res.* 8:1548. doi: 10.26888/f1000research.14926.1

Fode, C., Ma, Q., Casarosa, S., Ang, S. L., Anderson, D. J., and Guillomet, F. (2000). A role for neural differentiation genes in specifying the dorsoventral identity of telencephalic neurons. *Genes Dev.* 14, 67–80. doi: 10.1101/gad.14.1.67

Fregia, M., van Gestel, S. H. C., Linda, K., van der Raadt, J., Keller, J., Van Rhijn, J. R., et al. (2017). Rapid neuronal differentiation of induced pluripotent stem cells for measuring network activity on micro-electrode arrays. *J. Vis. Exp.* 119:54900. doi: 10.3791/54900

Flügge, S., Andersson, E., Thompson, L. H., Jönsson, M. E., Hebsgaard, J. B., Nissen, A., et al. (2009). Efficient production of mesencephalic dopamine neurons by Nlxl1 expression in embryonic stem cells. *Proc. Natl. Acad. Sci. U.S.A.* 106, 7613–7618. doi: 10.1073/pnas.0902396106

García-León, A. J., Kumar, M., Boon, R., Chau, D., One, J., Wolfs, E., et al. (2018). SOX10 single transcription factor-based fast and efficient generation...
of oligodendrocytes from human pluripotent stem cells. 

**Stem Cell Rep.** 10, 655–672. doi: 10.1016/j.stemcr.2017.12.014

Gascón, S., Murenzu, E., Masserdotti, G., Ortega, F., Russo, G. L., Petrik, D., et al. (2016). Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. 

**Cell Stem Cell** 18, 396–409. doi: 10.1016/j.stem.

Gennet, N., Gale, E., Nan, X., Farley, E., Takacs, K., Oberwallner, B., et al. (2011). Doublesex and mab-3-related transcription factor 5 promotes midbrain dopaminergic identity in pluripotent stem cells by enforcing a ventral-medial progenitor fate. 

**Proc. Natl. Acad. Sci. U.S.A.** 108, 9313–9316. doi: 10.1073/pnas.1016679108

Geoffroy, C. G., Critchley, J. A., Castro, D. S., Ramelli, S., Barraclough, C., Descombes, P., et al. (2009). Engineering of dominant active basic helix-loop-helix proteins that are resistant to negative regulation by postnatal central nervous system antigeneic cues. 

**Stem Cells** 27, 847–856. doi: 10.1002/stem.

Ghasemi-Kasman, M., Hajikaram, M., Baharvand, H., and Javan, M. (2015). MicroRNA-mediated in vitro and in vivo direct conversion of astrocytes to neuroblasts. 

**PLoS One** 10, e0127878. doi: 10.1371/journal.pone.0127878

Giorgeta, A., Marchetto, M. C. N., Li, M., Yu, D., Fazzina, R., Mu, Y., et al. (2012). Cord blood-derived neuronal cells by ectopic expression of Sox2 and c-Myc. 

**Proc. Natl. Acad. Sci. U.S.A.** 109, 12556–12561. doi: 10.1073/pnas.1209253109

Goparaju, S. K., Kohda, K., Ibata, K., Soma, A., Nakatake, Y., Akiyama, T., et al. (2017). Rapid differentiation of human pluripotent stem cells into functional neurons by mRNAs encoding transcription factors. 

**Sci. Rep.** 7:42367. doi: 10.1038/srep42367

Goto, K., Imamura, K., Komatsu, K., Aiba, K., Nakatsuji, N., et al. (2016). Simple direct specification of spiral motor neurons from ESCs/iPSCs using Sendai virus vectors. 

**Mol. Ther. Methods Clin. Dev.** 4, 115–125. doi: 10.1016/j.omtm.2016.12.007

Gralisli, S., Drouin-Ouellet, J., and Parmar, M. (2016). Brain repair and reprogramming: the route to clinical translation. 

**J. Intern. Med.** 280, 265–275. doi: 10.1111/jmi.12475

Greenway, D. W., Stief, M., Jeffries, A., and Buckley, N. J. (2007). R81 silencing transcription factor maintains a repressive chromatin environment in embryonic hippocampal neural stem cells. 

**Stem Cells** 25, 354–363. doi: 10.1634/stemcells.2006-0207

Guo, Z., Zhang, L., Wu, Z., Chen, Y., Wang, F., and Chen, G. (2014). In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. 

**Cell Stem Cell** 14, 188–202. doi: 10.1016/j.stem.2013.12.001

Hack, M. A., Sugimori, M., Lundberg, C., Nakafuku, M., and Götz, M. (2004). Regionalization and fate specification in neurosphere: the role of Olig2 and Pax6. 

**Mol. Cell. Neurosci.** 25, 664–678. doi: 10.1016/j.mcn.2003.12.012

Kim, Y., Zheng, X., Ansari, Z., Bunnell, M. C., Herdy, J. R., Traxler, L., et al. (2018). Rapid differentiation of human pluripotent stem cells into functional neurons from human embryonic stem cells. 

**Nat. Neurosci.** 21, 932–940. doi: 10.1038/s41593-018-0168-3

Kim, M., Sánchez, R., Schichor, C., Masserdotti, G., Ortega, F., Heinrich, C., et al. (2012). Reprogramming of periphere-derived cells of the adult human brain into induced neuronal cells. 

**Cell Stem Cell** 11, 471–476. doi: 10.1016/j.stem.2012.07.007

Kee, N., Volakakis, N., Kirkeby, A., Dahl, L., Storvall, H., Holmbäck, S., et al. (2017). Single-cell analysis reveals a close relationship between differentiating dopamine and subthalamic neuronal neuronal lineages. 

**Cell Stem Cell** 20, 29–40. doi: 10.1016/j.stem.2016.10.003

Kim, H.-J., McMillan, E., Han, F., and Svendsen, C. N. (2009). Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. 

**Stem Cells** 27, 390–398. doi: 10.1634/stemcells.2007-1047

Kim, J. H., Auerbach, J. M., Rodríguez-Gómez, J. A., Velasco, I., Levin, D., Lumelsky, N., et al. (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. 

**Nature** 418, 50–56. doi: 10.1038/nature00900

Kim, J. Y., Koh, H. C., Lee, J. Y., Chang, M. Y., Kim, Y. C., Chung, H. Y., et al. (2003). Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression. 

**J. Neurochem.** 85, 1443–1454. doi: 10.1046/j.1471-4159.2003.01780.x

Kim, Y., Zheng, X., Ansari, Z., Bunnell, M. C., Herdy, J. R., Traxler, L., et al. (2018). Mitochondrial aging defects emerge in directly reprogrammed human neurons due to their metabolic profile. 

**Cell Rep.** 23, 2550–2558. doi: 10.1016/j.celrep.2018.04.105

Kirkeby, A., Grealish, S., Wolf, D. A., Nelander, J., Wood, J., Lundblad, M., et al. (2012). Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. 

**Cell Rep.** 1, 703–714. doi: 10.1016/j.celrep.2012.04.009

Kirkeby, A., Holmbäck, S., Tkalčuk, K., Heuer, A., Kee, N., Cardoso, T., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. 

**Cell Stem Cell** 20, 135–148. doi: 10.1016/j.stem.2016.09.004

Kittappa, R., Chang, W. W., Awatramani, R. B., and McKay, R. D. G. (2007). The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. 

**PLoS Biol.** 5:e325. doi: 10.1371/journal.pbio.0050325

Krocik, R., and Zhang, S.-C. (2011). Directed differentiation of functional astroglial subtypes from human pluripotent stem cells. 

**Nat. Protoc.** 6, 1710–1717. doi: 10.1038/nprot.2014.371

Kris, S., Shim, J. W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. 

**Nature** 480, 547–551. doi: 10.1038/nature10648
Kronenberg, G., Gertz, K., Cheung, G., Buffo, A., Kettenmann, H., Götz, M., et al. (2010). Modulation of fate determinants Olig2 and Pax6 in resident glia evokes spiking neuroblasts in a model of mild brain ischemia. *Stroke* 41, 2944–2949. doi: 10.1161/STROKEAHA.110.583039

Kuhn, S., Gritti, L., Crooks, D., and Dombrowski, Y. (2019). Oligodendrocytes in development, myelin generation and beyond. *Cells* 8:1424. doi: 10.3390/cells8111424

La Manno, G., Gyllborg, D., Codeluppi, S., Nishimura, K., Salto, C., Zeisel, A., et al. (2016). Molecular diversity of midbrain development in mouse, human, and stem cells. *Cell* 167, 566–580.e19. doi: 10.1016/j.cell.2016.09.027

Li, P., Li, M., Tang, X., Wang, S., Zhang, Y. A., and Chen, Z. (2016). *Frontiers in Cellular Neuroscience* [www.frontiersin.org](http://www.frontiersin.org)

Li, X., Tang, Y., Bradley, R., Du, Z., Tao, Y., Kong, L., et al. (2018). Fast generation of functional subtype astrocytes from human pluripotent stem cells. *Cell Stem Cell* 11, 988–1008. doi: 10.1016/j.stem.2018.08.019

Li, X., Tzeng, S. Y., Liu, X., Tammia, M., Cheng, Y.-H., Rolfe, A., et al. (2016). Nanoparticle-mediated transcriptional modifications enhances neuronal differentiation of human neural stem cells following transplantation in rat brain. *Biomaterials* 84, 157–166. doi: 10.1016/j.physbeh.2017.03.040

Li, Y., Guo, B., Yang, R., Xiao, Z., Gao, X., Yu, J., et al. (2018). A novel long noncoding RNA Inc158 promotes the differentiation of mouse neural precursor cells into oligodendrocytes by targeting nuclear factor-IB. *Neuroreport* 29, 1121–1128. doi: 10.1097/WNR.0000000000001083

Li, X., Tzeng, S. Y., Zamboni, C. G., Koliatsos, V. E., Ming, G., Green, J. J., et al. (2017). Enhancing oligodendrocyte differentiation by transient transcription activation via DNA nanoparticle-mediated transfection. *Acta Biomater.* 54, 249–258. doi: 10.1016/j.actbio.2017.03.032

Liang, Q., Xia, W., Li, W., and Jiao, J. (2018). RNF20 controls astrocytic spiking neuroblasts in a model of mild brain ischemia. *Neuron* 101, 472–485. doi: 10.1016/j.neuron.2017.12.010

Matjusaitis, M., Wagstaff, L. J., Martella, A., Baranowski, B., Blin, C., Gogolok, S., et al. (2019). Reprogramming of fibroblasts to oligodendrocyte progenitor-like cells using CRISPR/Cas9-based synthetic transcription factors. *Cell Stem Cell* 30, 932–946.e7. doi: 10.1016/j.stemcr.2019.04.058

Mazzara, P. G., Massimino, L., Pellegratta, M., Ronchi, G., Ricca, A., Iannielli, A., et al. (2017). Two factor-based reprogramming of rodent and human fibroblasts into Schwann cells. *Nat. Commun.* 8:14088. doi: 10.1038/ncomms14088

Mazzoni, E. O., Mahony, S., Closser, M., Morrison, C. A., Nedeleeck, S., Willms, D. J., et al. (2013). Synergistic binding of transcription factors to cell-specific enhancers programs motor neuron identity. *Nat. Neurosci.* 16, 1219–1227. doi: 10.1038/nn.3467

Meijer, M., Rehbach, K., Brunner, J. W., Classen, J. A., Lammerse, H. C. A., van Linge, L. A., et al. (2019). A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons. *Cell Rep.* 27, 2199–2211. doi: 10.1016/j.celrep.2019.04.058

Mertens, J., Paquila, A. C. M., Ku, M., Hatch, E., Böhnke, L., Ladjevardi, S., et al. (2015). Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocyttoplasmic defects. *Cell Stem Cell* 17, 705–718. doi: 10.1016/j.stem.2015.09.001

Mong, J., Panman, L., Alexeeoonko, Z., Kee, N. E., Stanton, L. W., Ericson, J., et al. (2013). Transcription factor-induced lineage programming of noradrenaline and motor neurons from embryonic stem cells. *Stem Cells* 32, 604–622. doi: 10.1002/stem.1458

Najm, F. J., Lager, A. M., Zaremba, A., Wyatt, K., Capriniello, A. V., Factor, D. C., et al. (2013). Transcription factor-mediated reprogramming of fibroblasts to expandable, myelogenically oligodendrocyte progenitor cells. *Nat. Biotechnol.* 31, 426–433. doi: 10.1038/nbt.2561

Nehme, R., Zuccaro, E., Ghosh, S. D., Li, C., Sherwood, J. L., Pietilainen, O., et al. (2018). Combining NGN2 programing with developmental patterning generates human excitatory neurons with NMDAR-mediated synaptic transmission. *Cell Rep.* 23, 2509–2523. doi: 10.1016/j.celrep.2018.04.066

Nickolls, A. R., Lee, M. M., Espinoza, D. F., Sczotc, M., Lam, R. M., Wang, Q., et al. (2020). Transcriptional programming of human mechanosensory neuron subtypes from pluripotent stem cells. *Cell Rep.* 30, 932–946.e7. doi: 10.1016/j.celrep.2019.12.062

Nishiyama, A., Xin, L., Sharov, A. A., Thomas, M., Mowrer, G., Meyers, E., et al. (2009). Uncovering early response of gene regulatory networks in ESCs by systematic induction of transcription factors. *Cell Stem Cell* 5, 420–433. doi: 10.1016/j.stem.2009.07.012

Olova, N., Simpson, D. J., Marioni, R. E., and Chandra, T. (2019). Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. *Aging Cell* 18:e12877. doi: 10.1111/acel.12877

O’Shea, K. S. (2001). Neuronal differentiation of mouse embryonic stem cells: lineage selection and forced differentiation paradigms. *Blood Cells Mol. Dis.* 27, 705–712. doi: 10.1006/bcmd.2001.0435

Pang, Z. P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D. R., Yang, T. Q., et al. (2011). Induction of human neuronal cells by defined transcription factors. *Nature* 476, 220–223. doi: 10.1038/nature10202

Pannan, L., Andersson, E., Aleksenok, Z., Hedlund, E., Kee, N., Mong, J., et al. (2011). Transcription factor-induced lineage selection of stem-cell-derived neural progenitor cells. *Cell Stem Cell* 8, 663–675. doi: 10.1016/j.stem.2011.04.001

Park, C.-H., Kang, J. S., Shin, Y. H., Chang, M. Y., Chung, S., Koh, H.-C., et al. (2006). Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons. *FASEB J.* 20, 2553–2555. doi: 10.1096/fj.06-61599e

Pataskar, A., Jung, J., Smialowski, P., Noack, F., Calegari, F., Straub, T., et al. (2016). *NeuroD1 reprograms chratomin and transcription factor landscapes to induce the neuronal program. EMBO J.* 35, 24–45. doi: 10.1002/embj.201591206

Pattyn, A., Goridis, C., and Brulet, J. F. (2000). Specification of the central noradrenergic phenotype by the homeobox gene Phox2b. *Mol. Cell. Neurosci.* 15, 235–243. doi: 10.1006/mcne.1999.0825

Pattyn, A., Morin, X., Cremer, H., Goridis, C., and Brulet, J. F. (1997). Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. *Development* 124, 4065–4075.
Pawlowski, M., Ortmann, D., Bertero, A., Tavares, J. M., Pedersen, R. A., Vallier, L., et al. (2017). Inducible and deterministic forward programming of human pluripotent stem cells into neurons, skeletal myocytes, and oligodendrocytes. Stem Cell Rep. 8, 803–812. doi: 10.1016/j.stemcr.2017.02.016

Pesaresi, M., Sebastian-Perez, R., and Cosma, M. P. (2019). Dedifferentiation, transdifferentiation and cell fusion: in vivo reprogramming strategies for regenerative medicine. FEBS J. 286, 1074–1093. doi: 10.1111/febs.14633

Pfisterer, U., Kirkeby, A., Torper, O., Wood, J., Neland, J., Dufour, A., et al. (2011a). Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. U.S.A. 108, 10343–10348. doi: 10.1073/pnas.1105135108

Pfisterer, U., Wood, J., Nihlberg, K., Hallgren, O., Bjermer, L., Westergren-Thorsson, G., et al. (2011b). Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle 10, 3311–3316. doi: 10.4161/cc.10.19.17584

Polò, J. M., Liu, S., Figueroa, M. E., Kualalert, W., Emini, S., Tan, K. Y., et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848–855. doi: 10.1038/nbt.1667

Rhee, H. J., Shaib, A. H., Rebbach, K., Lee, C., Seif, P., Thomas, C., et al. (2019). An autaptic culture system for standardized analyses of iPS/CSC-derived human neurons. Cell Rep. 27, 2212–2228 e7. doi: 10.1016/j.celrep.2019.04.059

Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., et al. (2012). Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 11, 100–109. doi: 10.1016/j.stem.2012.05.018

Rivetti Di Val Cervo, P., Romanov, R. A., Spigolon, G., Masini, D., Martin-Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., et al. (2019). Restriction of neural precursor ability to respond to Nurr1 by early regional specification. PLoS One 7:e51798. doi: 10.1371/journal.pone.0051798

Song, Z., Jadali, A., Fritsch, B., and Kwan, K. Y. (2017). NEUROG1 regulates CDK2 to promote proliferation in otic progenitors. Stem Cell Rep. 9, 1516–1529. doi: 10.1016/j.stemcr.2017.09.011

Sowa, Y., Kishida, T., Tomita, K., Yamamoto, K., Numajiri, T., and Mazda, O. (2017). Direct conversion of human fibroblasts into Schwann cells that facilitate regeneration of injured peripheral nerve in vivo. Stem Cells Transl. Med. 6, 1207–1216. doi: 10.5966/sctm.2012-0084

Srivastava, D., and DeWitt, N. (2016). In vivo cellular reprogramming: the next generation. Cell 166, 1386–1396. doi: 10.1016/j.cell.2016.08.055

Suigumori, M., Nagao, M., Parras, C. M., Nakatani, H., Lebel, M., Guillomet, F., et al. (2008). Ascl1 is required for oligodendrocyte development in the spinal cord. Development 135, 1271–1281. doi: 10.1242/dev.015570

Sun, A. X., Yuan, Q., Tan, S., Xiao, Y., Wang, D., Khoo, A. T. T., et al. (2016). Direct induction and functional maturation of forebrain GABAergic neurons from human pluripotent stem cells. Cell Rep. 16, 1942–1953. doi: 10.1016/j.celrep.2015.10.035

Sun, Y., Nadal-Vicens, M., Misono, S., Lin, M. Z., Zubiaga, A., Hua, X., et al. (2001). Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. Cell 104, 365–376. doi: 10.1016/s0092-8674(01)00224-0

Surmazc, B., Noisà, P., Risner-Janické, J. R., Hui, K., Ungleß, M., Cui, W., et al. (2012). DLK1 promotes neurogenesis of human and mouse pluripotent stem cell-derived neural progenitors via modulating Notch and BMP signalling. Stem Cell Rep. 8, 459–471. doi: 10.1007/s41587-019-0035-0

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872. doi: 10.1016/j.cell.2007.11.019

Takahashi, K., and Yamanaka, S. (2006). Induction of specific neuron types by overexpression of single lineage transcription factors. Stem Cells Dev. 15, 803–812. doi: 10.1089/sctm.2012-0084

Tan, X. F., Qin, J. B., Jin, G. H., Tian, M. L., Li, H. M., Zhu, H. X., et al. (2010). Effects of Brn-4 on the neuronal differentiation of neural stem cells derived from rat midbrain. Cell Biol. Int. 34, 877–882. doi: 10.1002/cibi.20100214

Tang, Y., Liu, M. L., Zang, T., and Zhang, C. L. (2017). Direct reprogramming rather than iPS-based reprogramming maintains aging hallmarks in human motor neurons. Front. Mol. Neurosci. 10:359. doi: 10.3389/fnmol.2017.00359

Tao, Y., and Zhang, S. C. (2016). Neural subtype specification from human pluripotent stem cells. Cell Stem Cell 19, 573–586. doi: 10.1016/j.stem.2016.10.015

Thieh, J., Calder, E. L., Guttiokonda, S. R., Gutzwiller, E. M., Amorolmakan, K. A., Steinbeck, J. A., et al. (2019). NFIA is a gliogenic switch enabling rapid deriviation of functional human astrocytes from pluripotent stem cells. Nat. Biotechnol. 37, 267–275. doi: 10.1038/s41587-019-0033-0

Terasaki-Ota, Y., Yamamizu, K., Piao, Y., Sharova, L., Amano, M., Yu, H., et al. (2016). Induction of specific neuron types by overexpression of single transcription factors. In Vitro Cell. Dev. Biol. Anim. 52, 961–973. doi: 10.1007/s11626-016-0056-7

Thek, I., Caiazzo, M., Dvoretskova, E., Leo, D., Ungaro, F., Curreli, S., et al. (2013). Rapid generation of functional dopaminergic neurons from human induced pluripotent stem cells through a single-step procedure using cell lineage transcription factors. Stem Cells Transl. Med. 2, 473–479. doi: 10.5966/sctm.2012-0133

Thoma, E. C., Wismhneyer, E., Offen, N., Maurus, K., Sirén, A. L., Schartl, M., et al. (2012).李某 generation of neural stem cell differentiation into neurons. Neurosci. Res. 67, 8–17. doi: 10.1016/j.neures.2010.01.007

Smith, D. K., Yang, J., Liu, M. L., and Zhang, C. L. (2016). Small molecules modulate chromatin accessibility to promote NEUROG2 mediated fibroblast-to-neuron reprogramming. Stem Cell Rep. 7, 955–969. doi: 10.1016/j.stemcr.2016.09.013

Soldati, C., Cacci, E., Biagioli, S., Carucci, N., Lupo, G., Perrone-Capano, C., et al. (2012). Restriction of neural precursor ability to respond to Nurr1 by early regional specification. PLoS One 7:e51798. doi: 10.1371/journal.pone.0051798

Song, Z., Jadali, A., Fritsch, B., and Kwan, K. Y. (2017). NEUROG1 regulates CDK2 to promote proliferation in otic progenitors. Stem Cell Rep. 9, 1516–1529. doi: 10.1016/j.stemcr.2017.09.011

Tian, M., Zhang, X., Qin, J., et al. (2010). The role of Brn-4 in the regulation of neural stem cell differentiation into neurons. Neurosci. Res. 67, 8–17. doi: 10.1016/j.neures.2010.01.007

Shi, J., Jin, G., Zhu, H., Tian, M., Zhang, X., Qin, J., et al. (2010). The role of Brn-4 in the regulation of neural stem cell differentiation into neurons. Neurosci. Res. 67, 8–17. doi: 10.1016/j.neures.2010.01.007
Weng, R., Lu, C., Liu, X., Li, G., Lan, Y., Qiao, J., et al. (2018). Long noncoding RNA-1604 orchestrates neural differentiation through the miR-200c/ZEB axis. Cell Rep., 15, 1221–1233. doi: 10.1016/j.celrep.2015.07.019

Wang, J., Pol, S. U., Haberman, A. K., Wang, C., O’Bara, M. A., and Sim, F. J. (2014). Transcription factor induction of human oligodendrocyte progenitor fate and differentiation. Proc. Natl. Acad. Sci. U.S.A. 111, E2885–E2894. doi: 10.1073/pnas.1408295111

Wapinski, O., L., Vierbuchen, T., Qu, K., Lee, Q. Y., Chanda, S., Fuenteas, D. R., et al. (2013). Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 155, 621–635. doi: 10.1016/j.cell.2013.09.028

Weng, R., Lu, C., Liu, X., Li, G., Lan, Y., Qiao, J., et al. (2018). Long noncoding RNA-1604 orchestrates neural differentiation through the miR-200c/ZEB axis. Cell Rep., 15, 1221–1233. doi: 10.1016/j.celrep.2015.07.019

Xue, Y., Zhan, X., Sun, S., Karuppagounder, S. S., Xia, S., Dawson, V. L., et al. (2019). Synthetic miRNAs drive highly efficient iPSC cell differentiation to dopaminergic neurons. Stem Cells Transl. Med. 8, 112–123. doi: 10.1002/sc tm.18-0036

Yamamizu, K., Piao, Y., Sharov, A. A., Zsiros, V., Yu, H., Nakazawa, K., et al. (2013). Identification of transcription factors for lineage-specific ESC differentiation. Stem Cell Rep. 1, 545–559. doi: 10.1016/j.stemcr.2013.05.006

Yamamizu, K., Sharov, A. A., Piao, Y., Amano, M., Yu, H., Nishiyama, A., et al. (2016). Generation and gene expression profiling of 48 transcription-factor-inducible mouse embryonic stem cell lines. Sci. Rep. 6:25567. doi: 10.1038/srep25567

Yang, N., Chanda, S., Marro, S., Ng, Y. H., Janas, J. A., Haag, D., et al. (2017). Generation of pure GABAergic neurons by transcription factor programming. Nat. Methods 14, 621–628. doi: 10.1038/nmeth.4291

Yang, N., Zuchero, J. B., Ahlenius, H., Marro, S., Ng, Y. H., Vierbuchen, T., et al. (2013). Generation of oligodendroglial cells by direct lineage conversion. Nat. Biotechnol. 31, 434–439. doi: 10.1038/nbt.2564

Yang, S., Toledo, E. M., Rosmaninho, P., Peng, C., Uhlén, P., Castro, D. S., et al. (2018). A Zeb2-miR-200c loop controls midbrain dopaminergic neuron neurogenesis and migration. Commun. Biol. 1:75. doi: 10.1038/s42003-018-0080-0

Yang, Y., Jiao, J., Gao, R., Le, R., Kou, X., Zhao, Y., et al. (2015). Enhanced rejuvenation in induced pluripotent stem cell-derived neurons compared with directly converted neurons from an aged mouse. Stem Cells Dev. 24, 2767–2777. doi: 10.1089/scd.2015.0137

Yuan, F., Chen, X., Fang, K. H., Wang, Y., Lin, M., Xu, S. B., et al. (2018). Induction of human somatostatin and parvalbumin neurons by expressing a single transcription factor LIM homeobox 6. eLife 7:e37382. doi: 10.7554/eLife.37382

Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785–798. doi: 10.1016/j.neuron.2013.05.029

Zhao, X., He, X., Han, X., Yu, Y., Ye, F., Chen, Y., et al. (2010). MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 65, 612–626. doi: 10.1016/j.neuron.2010.02.018

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.